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Summary 
Accurate diagnosis and early treatment are key in achieving global targets to end tuberculosis 
(TB). Between 2000 and 2017, nearly 54 million deaths were averted due to timely diagnosis 
and treatment initiation. Xpert MTB/RIF (“Xpert”¸Cepheid, Sunnyvale, CA, US) is a molecular 
diagnostic test with integration of an automated sample processing system and hemi-nested 
real time polymerase chain reaction (PCR) in a single cartridge. It provides results within two 
hours and can be used at point-of-care. Xpert was endorsed by WHO in 2010 and currently is 
strongly recommended for adults and children suspected for MDR-TB or HIV and conditionally 
for all suspected with TB, should resources allow. By 2016, approximately 34 million Xpert 
cartridges were procured globally. Despite considerable development in evaluation and roll out 
of Xpert, important questions still remain to be addressed. Xpert  has shown varibility in 
performance and it remains a question whether the  observed variability is entirely explained 
by differences in populations and epidemiological burden  or methodological differences in how 
Xpert  is being evaluated such as effect of time to positivity (TTP) on a reference standard 
(culture) on sensitivity and how previous history of TB affects the specificity of Xpert. Accurate 
TTP can only be determined in automated systems such as MGIT culture system. Furthermore, 
studies that have assessed patient-important outcomes have shown inconsistent results. This 
doctoral thesis provides evidence on the overall population level pooled effect of Xpert on 
important patient outcomes based on the Cochrane review and evidence on effect of TTP and 
history of TB on sensitivity and specificity Xpert, respectively. 
This thesis is based on three manuscripts: 
Manuscript 1: Effect of time to culture positivity as a reference standard on Xpert 
MTB/RIF sensitivity for diagnosis of pulmonary tuberculosis 
This manuscript shows the effect of TTP on the sensitivity of Xpert based on the analysis of 
data from a database of 16 different studies that evaluated Xpert with a total of 11,870 
participants from ten different countries. The TTP was divided up in categories of five days up 
to 42 days. In all culture positive, sensitivity of Xpert in categories up to 15 days were: ≤ 5, 
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99.3% , (95% CI: 95-100, N=351) , >5≤10, 99.3 % (95%CI, 98.4-99.7, N=2231)  and >10≤15, 
96.8% (95%CI,94-98.3,N=1885). In smear negative-culture positive: ≤ 5, 99%, (95% CI: 62-
100, N=37) , >5≤10, 98% (95%CI, 80-100, N=237)  and >10≤15, 92% (95%CI,83-96 ,N=413). 
In HIV positive: ≤ 5, 96% , (95% CI: 63-100, N=51) , >5≤10, 98% (95%CI, 90-100, N=199)  and 
>10≤15, 94% (95%CI,82-98 ,N=168) The sensitivity of Xpert in the first fifteen days was high 
in all three groups of analysis: all culture positive, smear positive-culture positive and smear 
negative-culture positive and irrespective of HIV status. A significant drop in sensitivity of Xpert 
when TTP of more than 15 days were assessd across all groups of analysis. Xpert sensitivity 
decreased with increasing TTP. This may explain some of the variation seen across different 
studies published on the diagnostic performance of Xpert. In settings with better TB control 
efforts, it is expected that patients are diagnosed earlier and TTP will be increased. Thus, 
reporting TTP of MGIT culture is important to ensure comparability of studies on Xpert as a 
diagnostic TB test. 
Manuscript 2: Effect of a previous history of tuberculosis on the specificity of Xpert 
MTB/RIF 
This manuscript shows the effect of history of TB based on the analysis of data from a database 
of 16 different studies that evaluated Xpert with a total of 11,870 participants. A total of 1,630 
participants had a history of TB. The median time since previous TB treatment was 3 years 
(Interquartile range (IQR), 0.0-6). Among the 803 patients with a TB episode within two years 
of testing, the specificity of Xpert was 92.2% (95% CI 81-97). The specificity increased with 
time since previous TB. Between two and five years (373 participants), the specificity was 
99.0% (95% CI; 86-100) and above five years (454 participants), 98.6% (95% CI; 85.4-
99.8).This manuscript shows that a history of TB negatively affects Xpert specificity, and this 
effect is increased among those with TB in the last two years. This implies  for a need of 
algorithms in patients with history of TB and positive Xpert to guide interpretation and 
management. The use of chest X-ray and clinical judgement remain relevant. 
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Manuscript 3: Impact of the diagnostic test Xpert MTB/RIF® on health outcomes for 
tuberculosis 
This manuscript is based on a Cochrane review and summarizes the effect of Xpert on patient-
important outcomes. The review included ten studies, seven of which were randomized 
controlled trials and three pre-post intervention studies. In the domains of the Cochrane risk of 
bias tool, most randomized studies had a low risk of bias. There was evidence of a positive 
effect of Xpert on tuberculosis confirmation in treated patients (RR 1.29 95%CI 1.11, 1.51 in 
the randomized trials) and reduction in pre-treatment loss to follow up (RR 0.59 95% CI 0.42-
0.84). Overall there was a reduction on all-cause mortality of 12% (RR 0.88 (95% CI 0.73, 
1.05) and 24% (RR 0.76 95% CI 0.58-1.00) among HIV positive participants. There was 
evidence that Xpert lead to an increase in the overall proportion of patients treated for TB (RR 
1.10 95%CI 0.98, 1.23), the likelihood of being cured (OR 1.09 95% CI 1.02, 1.16), and that 
the proportion of those treated who were not microbiologically confirmed was reduced (RR 
0.59 95%CI 0.41 0.85. This manuscript shows that compared with smear microscopy, Xpert 
reduces all-cause mortality by 12% although uncertainty around the effect estimate was high 
and the data was also compatible with reduction of up to 27% and an increase of up to 5%. 
The mechanisms by which Xpert could affect mortality is likely at least in part related to the 
reduction in pre-treatment loss to follow-up as well as the increase in the proportion of patients 
cured. Further studies should assess the role of empirical treatment on the impact of Xpert on 
patient outcomes.  
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1 Chapter 1 
1.1 Introduction  
1.1.1 Biology, transmission and clinical manifestation 
Tuberculosis (TB) in human is caused by intracellular bacteria known as Mycobacterium 
tuberculosis sensu strictu and Mycobacterium africanuum belonging to the Mycobacterium 
tuberculosis complex (MTBC) (1). The MTBC consists of highly related bacterial lineages with 
nucleotide similiarity of 99.9%, except Mycobacterium canettii which differs markedly from the 
rest of the MTBC members (1). Other animal-associated members of the MTBC are 
responsible for diseases in wild and domestic mammalian hosts.  
Scientific evidence suggests that MTBC emerged about 10,000 years ago in Africa and 
migrated with modern human to the rest of the world during the neolithic period (2). However, 
the matching of MTBC and human mitochondrial phylogeny suggest much older 
interrelationship, that carriage of MTBC in human was present in the hunters and gathers who 
migrated from Africa nearly 70,000 years ago (2).  
There are seven human adapted MTBC lineages. Mycobacterium tuberculosis sensu strictu 
comprises of lineages 1 to 4 and lineage 7. Mycobacterium africanum comprises lineage 5 and 
6. MTBC lineages show geographic distribution variations, for example lineage 5 and 6 are 
restricted to West Africa and lineage 7 only occurs in Ethiopia, Figure 1. 1). Lineage 4 is the 
most widely distributed across the world (1). MTBC lineage variation has an impact on 
virulence and hence important for vaccine and drug development. The Xpert MTB/RIF test 
(Xpert), which is the central topic of this thesis, can detect the entire MTBC across all lineages. 
TB transimission occur mainly through air from a TB patient to another person through released 
aerosals either by coughing, sneezing, speaking or spiting (3). It is estimated that a single 
sneeze can release up to 40,000 droplets and each of the droplets can potentially transmit TB 
(4). Untreated patients with active TB disease can potentially infect 10 to 15 individuals per 
year. The risk of TB transmission depends on many factors such as quantity of infectious 
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droplets released, immunity of uninfected person, virulences of the Mycobacterium 
tuberculosis strain, overcrowding, close contact and duration of exposure (5, 6). 
Worldwide, about 1.7 billion people are latently infected with TB. These asymptomatically 
infected individuals have about 12% life time risk of progressing to active TB disease. If no 
active disease develops after five years, the risk drops to 2% and to 0.5% after 10 years (7). 
However, with HIV co-infection, the risk to progression increase to about 10% annually. These 
figures refer to a simplistic classification with latent, asymptomatic and not infectious TB on the 
one hand, and active, often infectious TB on the other hand. Recent evidence suggests, 
however, that TB infection should be considered as a spectrum, which ranges from eliminated 
disease to active, sub-clinical TB to active, clinical TB (7). Primary infection occurs when MTBC 
enters the lungs of an uninfected person. Depending on factors such as infectious dose and 
immunity of an individual, the infected person might control the infection and bacteria remain 
in the lungs without causing any symptoms. This is also known as latent infection, which can 
be stable or unstable. A stable latent infection  is rapidly controlled and the organism may be 
sterilized, which minimises risk of reactivation (7). In the unstable latent infection the infection 
takes a waxing and waning course with high chances of reactivation or progression to active 
TB in the presence of precipitating factors e.g. malnutrition (7). Clinically, pulmonary TB 
presents usually with cardinal features of prolonged cough of more than two weeks or 
hemoptysis, fever, night sweats and loss of weight. Other symptoms may include fatigue and 
loss of appetite.  TB manifestation outside the  the lungs, also known as extra-pulmonary TB, 
may occur from haematogenous dissemination with varying symptoms depending on the 
organs affected by the pathogen.  
Figure 1. 1 The Nature and Evolution of Genomic diversity of in the Mycobacterium tuberculosis Complex 
(1) 
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1.1.2 TB epidemiology and control 
TB is one of the oldest dieases of humankind. In the past three centuries, TB was responsible 
for 25% of all death in Europe and America (8). TB is the leading cause of death from a single 
infectious disease (9). According to the recent World Health Organization (WHO) TB report of 
2018, 1.2 million HIV-negative and 251,000 HIV-positive were estimated to have died of TB 
(9). In the same year, of the estimated 10 million new TB infections only 70% were reported 
(9). About 0.8 million cases were co-infected with HIV (9). Although TB cases were reported 
from all countries, two third of the total estimated TB were reported from eight countries; India, 
China, Indonesia, the Philippines, Pakistan, Nigeria Bangladesh and South Africa (9).  
Drug resistant TB (DR-TB) was reported in 186,772 cases globally and about one in three was 
enrolled in treatment (9), accounting for only 25% of the total estimated global burden. China 
and India accounted for 43% of the DR-TB treatment gap (9).  It is estimated that about 20% 
of all TB bacteria isolated globally is at least resistant to one major first or second line drug 
(10). Approximately 5% of patients worldwide are estimate to have TB, which is either resistant 
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to both isonizid and rifampicin known as MDR, or in addtion resistant to secondline 
floroquinolones or injectables of  aminoglycosides (10).   
In both drug sensitive and drug resistant TB, underreporting and/or underdiagnosis still exist. 
In 2018, India, Nigera, Indonesia and Phillipines acounted for more than half of the diagnostic 
gap (9). A number of challenges are related to the diagnostic gap and these include but not 
limited to: limited access to healthcare and lack of robust diagnostic tools at point of care. 
In 2000, a partnership of 1,500 organizations, which include a wide range of stakeholders, was 
formed in efforts to elimiate TB. WHO endorsed the Stop TB Partneship to coordinate and 
spearhead efforts in TB control. The global end TB  targets were made in 2015 and recognizes 
the need for a world free of TB. In order to achieve that, the Stop TB partneship has set targets 
to be achieved by 2035. Compared to 2015: (i) reduce the number of death by 95% (ii) reduce 
TB incidence rate by 90% and (iii) 0% TB-affected families facing catastrophic costs due to TB 
(11). In order to reliaze the end TB strategy targets, TB  must have declined at a rate of 10% 
annually between 2015 and 2020, and should decline at a rate of 17% after 2020. As of 2018, 
the current decline of TB is only at 2% per annum (9). Furthermore, the end TB strategy calls 
for universal access to drug susceptibility testing among patients seeking healthcare. Indeed, 
optimization of current strategies and introduction of new tools particularly diagnostic tools 
cannot be overemphasized (11). 
Figure 1. 2: Estimated TB incidence rates in 2018 (9) 
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1.1.3 TB diagnosis  
1.1.3.1 Current standard of care for bacteriological confirmation of TB 
Smear microscopy for TB was introduced approximately 100 years ago, and has been used to 
confirm TB ever since. The sensitivity of smear microscopy ranges between 20 and 60% (12). 
However, smear microscopy is known to be highly specific for TB, with specificity above 98% 
(12). Smear microscopy is relatively simple, inexpensive and identifies most infectious TB 
patients (12). Although the sensitivity for TB is limited, smear microscopy is still widely used in 
low and middle income countries where 95% of all cases and 98% of all TB related death occur 
(12).  Furthermore, it has limited value in patients with low bacterial load particularly children 
and among HIV co-infected individuals. In drug resistance TB, smear microscopy has no value 
as it does not have capacity for resistance detection. 
Culture is the the reference standard fo diagnosis of TB and was first described over 50 years 
ago. Ever since, culture has undergone several developments and to date, culture can be done 
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in both liquid and solid media. Mycobacteria growth indicator tubes (MGIT) liquid culture can 
show growth within 42 days after innoculation. Over time the MGIT culture evolved to current 
automated version known as BACTEC MGIT 960 system (MGIT Becton Dickson , Franklin 
Lakes, NJ, USA) (13, 14). MGIT 960 system consists of broth medium and a flurochrome 
compound, which leads to fluorescence as bacteria utilize oxygen while growing. (13, 14). TB 
is detected at a time to positivity when the estimated colony forming unit CFU per ml is 105 to 
106 in the media (13). Negative culture is declared after 42 days of innoculation (13, 14). 
Löwenstein-Jensen (LJ)  culture uses solid media e.g. egg based media. LJ has been used for 
many years and it is considered  economical and easy to prepare. In general, LJ is associated 
with low rate of contamination. However, LJ culture takes longer time to grow, up to eight 
weeks after innoculation (14). 
Establishment of both liquid and solid cultures require specified conditions of infection control. 
Biosafety level 3 facilities require expensive infrastructures and specialized trainings both of 
which limit the use of culture at point-of-care in low- and middle-income countries. 
 
1.1.3.2 Development of new TB diagnostics 
In the UNITAID Diagnostic Technology Landsscape report, the Foundation for Innovative New 
Diagnostics (FIND) classifies development of Nucleic  Acid Amplification Tests (NAATs) 
diagnostics assay based on the degree of complexity of use (15). The majority of diagnostic 
technologies are in the development stages with few under WHO evaluation (15), Appendix 1. 
So far,  the following have received WHO recommendations for TB or MDR detection: lateral 
flow-lipoarabinomannan (LAM) assay, loop mediated amplification (LAMP) assay, line probe 
assay (LPA), the current Xpert assay and Xpert MTB/RIF Ultra (Ultra) (15). The current 
diagnostic pipeline calls for developers to accelearate development of NAAT that meet 
targeted product profile and can be readily available at point-of-care. Xpert remains  the most 
widely used at point of care of all NAATs endorsed by WHO. 
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1.1.3.3 Xpert MTB/RIF 
1.1.3.3.1 Technical characteristics 
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, US) is a molecular diagnostic test with integration 
of an automated sample processing system and hemi-nested real time polymerase chain 
reaction (PCR) in a single cartridge (16). The Xpert plastic cartridge contains  liquid sample 
processing, buffers and PCR reagents (17). Once a sample has been prepared and mixed in 
the cartridge, the cartidge is inserted in the GeneXpert instrument. The GeneXpert instrument 
controls intracartridge fluidics and performs real-time PCR (17). Xpert can simultaneously 
detect M. tuberculosis and susceptibility to rifampicin. Xpert amplifies sequences of the rpoB 
gene that are specific for MTBC and simultaneously probe for mutation in the Rifampicin 
Resistant Determinant Region (RRDR) of the rpoB gene (17). Xpert cartridge contain Bacillus 
globigii DNA as an internal control for sample processing and PCR (17). 
Initial clinical validation and implementation studies showed  Xpert can provide results within 
two hours and promising test performance in areas of intended use in both patients with 
pulmonary and extrapulmonary TB (18-20).  
1.1.3.3.2 Perfomance 
Xpert perfomance varies across different populations, type of TB,  specimen used and when 
different case definitions for TB were used (21-24). In a recent Cochrane review including 70 
studies and 37,237 participants, most studies done in high burden countries, the Xpert pooled 
sensitivity was 85% (82% to 88%) with a specificity of 98% (97% to 98%) among adults with 
pulmonary TB (25). For rifampicin resistance, including 48 studies and 8,020 participants, 
Xpert pooled sensitivity was 96% (94% to 97%) with a specificity of 98% (98% to 99%) (25). 
Among children, Xpert pooled sensitivity and specificity were 62% ( 51% to 73%) and 98% 
(97% to 98%), respectively, when expectorate or induced sputum were used (23). Xpert 
perfomance were comparable among studies that used gastric lavage samples (23). In a 
Cochrane review Xpert perfomance for extra-pulmonary TB was variable in different samples 
(cerebrospinal fluid (CSF), pleural fluid, urine, joint and bones) (22).  
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1.1.3.3.3 Policy and roll out 
In 2010, the WHO endorsed Xpert in 2010 after an expert meeting which reviewed exisiting 
evidence on accuracy. By early 2011, the WHO recommeded the use of Xpert as an initial 
diagnostic test in individuals suspected of having MDR-TB or HIV-associated TB, as a strong 
recommendation (26). Furthermore, conditional recommendations were made that Xpert 
should be used as a follow up test to smear microscopy in settings where MDR-TB and HIV 
are of lesser concern, particularly for further testing of smear negative patients (26). These 
recommendations were based mainly on studies done in adults. Following availability of new 
evidence, WHO convened another expert meeting in 2013. Additional  two strong 
recommendations were made; (i) Xpert should be used rather than conventional microscopy, 
culture and DST as initial diagnostic test in children suspect of MDR-TB or HIV associated TB, 
(ii) Xpert  should be used in preference of conventional microscopy and culture as the initial 
diagnostic for CSF specimen for patients suspected of TB meningitis. Further conditional 
recommendations included using Xpert as initial diagnostic test in non-respiratory specimens 
in extra-pulmonary TB and in all adults and children depending on resource availability (26).  
FIND negotiated with Cepheid for concessional pricing for Xpert in the public sector and for 
non-govermental organizations (NGO) in 145 high burden developing countries for 17,000 
USD per GeneXpert platform and 16.68 USD per cartridge (27). Following support from 
PEPFAR, USAID, UNITAID and BMGF the price was further reduced to 9.98 USD per cartridge 
(27). By 2016 approximately 23 million Xpert cartridge were procured in pubic sector in 130 
countries and approximately 34.4 millon overall globally (28, 29). Out of 22 high burden 
countries, 10 had included Xpert  in their national policy as the initial diagnostic for all presumed 
to have TB (29). The smear/ Xpert  ratio in these countries decreased between 2014 and 2016 
from a median of 32.2 smears for each Xpert  test to 6 (29). South Africa had the highest 
decrease in ratio given that South Africa scaled up the use of  Xpert to replace smear 
microscopy as initial TB test (29). Concessional pricing indeed contributed to rapid scale up of 
use of Xpert in developing countries. However, there are still concerns on costs among 10 out 
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of 22 high TB burden countries where TB is primarily diagnosed in the private sector (30). In 
these countries, the average price per cartridge in private healthcare was 68.73 USD, which 
often impedes patient`s access to Xpert . 
The imperfect perfomance of Xpert,  particularly in smear-negative and HIV- associated TB, 
led to the development a next generation assay call Xpert MTB/RIF ultra (Ultra), which has 
more abillity to detect TB even at very low bacterial load (24, 31). Ultra has 5% more sensitivity 
but 3.2% less specificity than Xpert (31). Higher sensitivity were seen more among HIV positive 
and smear negative-culture positive patients, while decrease in specificity was more among 
patients with previous history of TB. WHO called for an expert meeting which concluded that 
Ultra was non-inferior to Xpert for diagnosis of TB and rifampicin detection and that current 
WHO reccomendations for Xpert  apply for Ultra as well (31). 
1.1.4 Evidence gaps 
Despite considerable development in evaluation and roll out of Xpert , important questions still 
remain to be addressed. Xpert  has shown varibility in performance and it remains a question 
whether the observed variability is entirely explained by differences in populations and 
epidemiological burden or methodological differences in how Xpert is being evaluated. 
Furthmore, clinical impact in terms of patient-important outcomes remains an open question 
on the public health impact of Xpert  in TB control. Clearly identified evidence gaps concern 
the effect of time to culture positivity  on Xpert sensitivity,  as well as the effect of a history of 
TB on the specificity performance of Xpert. Furthermore, the impact of Xpert on patient-
important outcomes is still underresearched.  These gaps are discribed in detail below. 
1.1.4.1 Time to culture positivity 
TTP has been shown to be a proxy of bacillary load of the sputum inoculum (32-35). Longer 
TTP have been shown to correlate with low bacillary load (32, 35, 36). Longer TTP have also 
been shown among smear negative patients whose sputum was induced. Xpert sensitivity was 
found to correlate with TTP (32). Longer TTP of 28 and 14 days were observed among patients 
with smear negative-culture positive and smear positive-culture positive TB, respectively (32). 
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Accuracy studies of Xpert have shown low sensitivity in smear negative-culture positive 
compared to smear positive-culture positive patients. It is hypthesized that variation in bacterial 
load may affect performance of Xpert and that differences in the perfomance of Xpert between 
studies may be partially be explained by different TTP. This remains to be proved in large study 
which takes into account patients from different population and epidemiological settings. 
The variation in the type of culture (liquid or solid) and number of cultures may affect 
performance evaluation of Xpert. For example, Dorman et al in their additional analysis, 
showed  higher sensitivity of Xpert  when a single liquid culture was considered as a reference 
standard compared to multiple cultures. However, these analyses had small sample sizes, 
therefore lacking enough power for a definite conclusion. 
1.1.4.2 A previous history of TB 
Studies have reported incidences of false Xpert  positive results among patients with a previous 
history of TB (37, 38). Arguably, in patients with a history of TB Xpert  detects dead M. 
tuberculosis bacilli (37-39). False positives among previous TB patients was shown to be likely 
if the previous TB event was more recent, had a chest X-ray not compatible with TB, HIV co-
infection and had high CT value consistent with low bacterial load (39, 40). A history of TB 
increases the pre-test probability for TB in these patients, and in settings of high HIV burden 
where rates of co-infections are high, a positive Xpert could either be false or true positive. A 
potential  risk of overtreatment in this sub-population  remains relevant. It is crucial that the 
time since previous TB event and the likelihood of a false positive is well characterized to better 
inform clinical decisions. Previous studies were either small or done in particular settings which 
affects generalizability. Thus, such evidences call for evaluation of such variability in large 
studies across different populations and epidemiological settings. 
1.1.4.3 Patient-important outcomes 
In terms of impact on patient-important outcomes, studies have shown inconsistent results (41-
46). Evidence shows limited impact of Xpert on mortality (41, 46), whereas other studies have 
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shown impact of Xpert on reducing time to treatment initiation, particularly among HIV positive 
individuals (42, 44). To date, there have been seven trials that have assessed the impact of 
Xpert on patient relevant outcomes (41-47). A recent meta-analysis  by Di Tanna GL et al 
2019, on the impact of Xpert on clinical outcomes could not conclude with certainity any impact 
of Xpert on mortality among outpatients tested for TB (48). For the mortality analysis, this 
review included only three of the seven randomized controlled trial available so far (48). Little 
is known on the impact of  Xpert on other intermediate patient-important outcomes such as 
pre-treatment loss to follow up. Furthermore, it remains crucial to quantify the effect of Xpert 
on bacteriological confirmation, treatment and treatment success. These outcomes were not 
reported by Di Tanna GL et al 2019. A gap still exists on the impact of Xpert on patient 
outcomes in drug resistant TB. While other studies have shown a positive effect of Xpert on 
reducing time to diagnosis and treatment initiation in drug resistance TB (49), others have 
shown negative effects on treatment outcomes among drug resistant TB (50). Patient-
important outcomes are crucial in determining the health and quality of life of the population. 
To summarize, further research using large sample sizes from TB patients in different 
epidemiological settings is needed to understand how time to culture positivity affects Xpert 
sensitivity and how much this effect contributes to the variation in  Xpert performance 
variability. Furthermore, we need to better understand the effect of a previous history of TB 
and duration since previous TB on the Xpert specificity. The only review on impact of Xpert on 
mortality did not show any positive effect given the small number of studies included at the 
time. Reviewes with larger sample sizes are likely to detect effects on mortality of Xpert should 
these effects exist. Such reviews should include a wide range of patient-important outcomes, 
including pre-treatment loss to follow up, to allow comphrehensive assessment of the impact 
of Xpert on patient-important outcomes. 
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This doctoral thesis provides evidence on the overall population level pooled effect of Xpert on 
important patient outcomes based on the Cochrane review. Furthermore, it provides evidence 
on the effect of TTP and a previous history of TB on the sensitivity and specificity Xpert. 
2 Chapter 2 
2.1 Thesis aim 
The main aim of this doctoral  thesis  was to understand factors influencing Xpert performance 
variability and its impact on patient-important outcomes. Two studies were conducted using 
database from samples collected from 10 countries by FIND (Belarus, Cambodia, Georgia, 
India, Italy, Moldovia, Peru, South Africa, Vietnam and Zimbabwe), representing different 
epidemiological settings. The third study was a Cochrane review.  
Manuscript 1:The first study aimed to assess the effect of time to culture positivity as a 
reference standard on Xpert sensitivity for diagnosis of pulmonary TB. Additional analysis was 
done to assess Xpert performance depending on number of culture and type of culture used. 
Comparison was made in three groups: all culture positive, smear positive-culture positive  and 
smear negative-culture positive. 
Manuscript 2: The second study aimed to assess the effect of a previous history of TB  on the 
specificity of Xpert. Categories of time since the previous history of TB were made and the 
specificity was estimated in each category. The risk of false positivity was calculated in different 
sub-groups  including HIV positive and negative TB patients. 
Manuscript 3: The third manuscript aimed to assess the impact of Xpert on health outcomes 
for TB. A Cochrane protocol (Cochrane Systematic Review - Intervention - Protocol 
Version published: 27 February 2018, doi.org/10.1002/14651858.CD012972) was 
published. The focus was on the following outcomes: mortality, pre-treatment loss to follow  up 
and proportions of patients (treated, treated and confirmed bacteriologically and treated 
without confirmation). Comparison was made between Xpert and smear microscopy 
strategies. 
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3.1.1 Abstract 
Background 
Xpert performance for tuberculosis (TB) detection is usually assessed against culture and 
varying sensitivity has been found across studies. This variation in Xpert performance may be 
due to substantially varying bacillary load and/or different choice of reference standards. We 
examined the sensitivity of Xpert against different reference standards (number and type of 
culture) and using time to culture positivity (TTP) from an automated Mycobacterium Growth 
Indicator Tube (MGIT) culture system as an indicator of the bacillary load. 
Methods 
A large database of sixteen studies performed for the purpose of supporting a biorepository 
was collated by the Foundation for Innovative New Diagnostics (FIND). Participants were 
recruited prospectively from sites in ten countries in South America, Africa, Asia and Europe. 
Participants gave two sputum samples each for liquid and solid cultures. TB was defined as at 
least one culture positive. Time to culture positivity (TTP) was estimated from automated 
Mycobacteria Growth Indicator Tube (“MGIT”; Becton Dickinson, Franklin Lakes, NJ, USA) as 
the difference in dates between inoculation and positivity. The TTP was divided up in 
categories of five days (≤ 5, >5≤10, >10≤15, >15≤20, >20≤25, >25≤30, >30≤35 and >35≤42 
days). The sensitivity of Xpert was estimated as the proportion of culture positive patients who 
were Xpert positive using logistic regression, for different categories of TTP. The culture 
reference standard was defined in two cultures of each, MGIT and LJ. Predefined sub group 
analyses were done by smear and HIV status. The sensitivity of Xpert was calculated as the 
proportion positive of those positive by the reference standard. Clustering by study was taken 
into account using a random effect. 
Findings 
We included 9,894 participants from the 16 studies. Of the 5,850 participants with positive 
MGIT culture, 76.3% had a TTP of equal or less than 15 days. The overall median TTP was 
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11 days (Interquartile range (IQR) 8-15). The overall sensitivity of Xpert was 88.1% (95% CI 
81.8 to 92.5). In all culture positive, sensitivity of Xpert in categories up to 15 days were: ≤ 5, 
99.3% , (95% CI: 95-100, N=351) , >5≤10, 99.3 % (95%CI, 98.4-99.7, N=2,231)  and >10≤15, 
96.8% (95%CI,94-98.3,N=1,885). In smear negative-culture positive: ≤ 5, 99%, (95% CI: 62-
100, N=37) , >5≤10, 98% (95%CI, 80-100, N=237)  and >10≤15, 92% (95%CI,83-96 ,N=413). 
In HIV positive: ≤ 5, 96% , (95% CI: 63-100, N=51) , >5≤10, 98% (95%CI, 90-100, N=199)  and 
>10≤15, 94% (95%CI,82-98 ,N=168) The sensitivity of Xpert in the first fifteen days was high 
in all three groups of analysis: all culture positive, smear positive-culture positive and smear 
negative-culture positive and irrespective of HIV status. 
We observed a significant drop in sensitivity of Xpert when TTP of more than 15 days were 
considered across all groups of analysis. Using different TB case definitions, sensitivity of Xpert 
was highest against a single culture of either MGIT or LJ compared to multiple cultures in each. 
Sensitivity of Xpert was highest against a single MGIT: 93.4% (95% CI 87.3-96.6) in all culture 
positive patients and in smear negative culture positive patients 78% (95% CI 58.9-89.8). The 
lowest sensitivity was observed against multiple LJ (N=7260), 78.7% (95% CI 62.2-89.3) in all 
culture positive and in smear-negative culture-positive 64.9% (95% CI 49.7-77.5). 
Conclusion 
Xpert sensitivity decreases with increasing TTP. This may explain some of the variation seen 
across different studies. In settings with better control efforts, it is expected that patients are 
diagnosed earlier and TTP will be increased. Thus, reporting TTP is important to ensure 
comparability of studies. The comparison against different definitions of culture positivity 
demonstrate the importance of comparability of reference standards across studies.  
3.1.2 Background 
 
Accurate diagnosis and early treatment are key in achieving global targets to end tuberculosis 
(TB). Between 2000 and 2017, nearly 54 million deaths were averted due to timely diagnosis 
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and treatment initiation (9). Xpert has transformed TB diagnosis since its introduction and 
recommendation by the World Health Organization (WHO) in 2010 (51-53). 
Compared to the standard method of smear microscopy, Xpert has the advantage that it is 
more sensitive and provides information on rifampicin resistance. A Cochrane review 
estimated a pooled sensitivity of Xpert to be 85% and a pooled specificity of 98% (54). 
However, the performance of Xpert has been shown to vary between studies, depending on 
population, settings and testing strategy (21-23). For example, the pooled sensitivity of Xpert 
in extra-pulmonary TB and in children varies depending on which specimen has been testing 
for Xpert sensitivity (22, 23). Further variation of Xpert sensitivity is dependent on bacillary load 
measured by smear microscopy and HIV co-infection across studies (25). 
The reference standard used for the evaluation of Xpert is culture. In solid culture, the 
decontaminated sputum pellet is incubated usually for a maximum of 56 days (55). Liquid 
cultures using Mycobacteria Growth Indicator Tube (“MGIT”; Becton Dickinson, Franklin 
Lakes, NJ, USA) are observed for a minimum of 42 days (56, 57). However, across studies 
the type of cultures (solid and/or liquid culture) and number of cultures varies, and may affect 
performance estimates of the index test as well as the bacillary load, which may vary across 
populations. For example, differences in the performance of Xpert between studies may be at 
least partially explained by different reference standards (number and type of cultures). For 
example, an increasing number of samples examined with culture is likely to result in 
decreasing sensitivity of the index test. It is also likely that Xpert performance varies 
substantially with different TTP and  this may lead to differences between accuracy studies. 
Another reason for variation between these studies might relate to the patients spectrum. 
Depending on the control efforts in countries, patients might present earlier or later in their 
disease. This might affect the bacillary load. While smear status, is one criteria by which the 
patient spectrum can be defined, the time to positivity (TTP) of culture is better proxy of 
bacterial load of the sputum inoculum (33). Not surprisingly, smear and Xpert positivity is 
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associated with TTP, with patients with lower TTP are more likely to be smear or Xpert positive. 
(36, 58, 59). 
The effects of TTP and the number of reference tests have not been systematically evaluated. 
We examined a large dataset from 16 studies to estimated the impact of time to culture 
positivity and different reference standard definitions on Xpert sensitivity. 
3.1.3 Methods 
 
We analysed data from sixteen previous studies on the accuracy of Xpert conducted as part 
of the biorepository efforts of FIND. While the studies were performed under different protocols, 
the protocols were aligned in respect to the aspects critical to this analysis and had used Xpert 
and a common reference standard testing with liquid and solid cultures that was standardized 
across studies. Further details on the individual studies are provided in the Appendix  4. 
Participants  
Participants were aged 18 years or older and were presumptive TB patients presenting in 
eleven countries (Belarus, Cambodia, Georgia, India, Italy, Moldovia, Peru, South Africa, 
Vietnam and Zimbabwe). Participants were excluded from the analysis if they were below 18 
years of age or had contaminated or missing culture or indeterminate or missing Xpert results 
of their initial sputum sample. Patients were enrolled between 13 June 2011 and 6 March 2018. 
Test Methods 
Index test 
The Xpert result of the initial sample only was considered in the analysis. Xpert results were 
reported as detected, not detected or indeterminate. Indeterminate Xpert results were 
excluded from the analysis. 
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Reference standard 
The TB case definitions were based on all four available culture results from two different 
sputum samples.  MGIT liquid culture, and solid culture on Löwenstein-Jensen medium testing 
were performed on each of the two sputum specimens. The presence of M.tb complex in solid 
or liquid culture was confirmed with MPT64 antigen detection and/or MTBDRplus, MTBC and 
CM/AS line probe assays (Hain Lifesciences, Nehren, Germany).  
Definite TB was defined if at least one culture was positive with confirmed M.tb. We explored 
Xpert sensitivity using different case definitions of culture positivity. Multiple MGIT and LJ were 
defined if results were available from the two sputum specimens cultured and single was based 
on the assumption of only one being available. For sensitivity of Xpert,  we calculated sensitivity 
of Xpert using MGIT only or LJ only  when two cultures were available for each as reference 
standards. Second, we assumed if only one culture (MGIT or LJ) was available as a reference 
standard and defined it that as single MGIT or LJ. We explored Xpert sensitivity using different 
case definitions of culture positivity based on reference standards. 
Time to culture positivity was estimated for MGIT only and was determined as the difference 
in days between the date of inoculation to MGIT vial and date of positivity or until 42 days. 
Cultures with negative results after 42 days were considered negative. Contaminated cultures 
were excluded from the analysis. 
Statistical analysis 
Sensitivity was estimated as the proportion of patients testing positive by Xpert of those 
positive by the reference standard. Logistic regression was used to estimate sensitivity 
accounting for clustering by study using a random effect. We estimated the sensitivity of Xpert 
by TTP by grouping TTP into 5 day categories (≤ 5, >5≤10, >10≤15, >15≤20, >20≤25, >25≤30, 
>30≤35 and >35≤42 days). The sensitivity was plotted by category of time to positivity, with 
95% confidence intervals. The sensitivity was estimated in three defined groups of culture 
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positive (all culture positive, smear positive-culture positive, smear negative-culture negative). 
Analyses were performed using Stata version 15 (stataCorp LLC, Texas, USA). 
3.1.4 Results 
 
There were 11,870 presumptive TB patients who were included in the 16 studies. We excluded 
1,841 (15%) patients (1,389 did not have Xpert results on initial sputum sample, 464 were 
missing or had contaminated culture results and 12 who were below 18). A total of 9,894 had 
Xpert test results and were included in the final analysis. Of these 57% (5,592/9,894 had Xpert 
positive and TB was confirmed in 5,485 and 690 of Xpert positive and negative, respectively, 
Figure 3. 1 . Of the entire cohort, 62% (6,175/9,894) were confirmed to have TB with at least 
one positive culture result. The majority were newly TB diagnosed patients 83% (N=5,175). 
The largest number of participants came from studies in Peru, Vietnam and South Africa, Table 
3. 1. Overall, 3,727 (37%) were female. The median age in the entire cohort was 35 years (IQR 
26-49) with highest median age among patients in Vietnam 42 (30-54) and lowest in Peru 30 
(23-45). HIV co-infection was common among patients in African countries (South Africa 60% 
(902/1,509) Zimbabwe 61% (51/102). 
The overall sensitivity of Xpert was 88.1% (95% CI, 81.8 to 92.5) in all patients with at least 
one culture positive (6,175 participants). In smear-positive-culture positive participants, 
sensitivity was 98.6% (95% CI, 96.6 to 99.4) and in smear negative-culture-positive was 64.9% 
(95% CI, 50.0 to 77.5) Table 3. 3. Among patients who were co-infected with HIV, Xpert 
sensitivity was 86.7% (95% CI, 76.8 to 92.7) (686 participants). In HIV negative patients, the 
sensitivity was 89.7% (95% CI, 82.8 to 94.0) (4,798 participants). 
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Figure 3. 1:  Flow diagram of included patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
TB-Tuberculosis 
Xpert-Xpert MTB/RIF 
Total participants for 
analyses 
N=11,870 
 
Excluded from analysis 
12 below 18 years of age 
464  missing culture results  
1,365 Missing Xpert on initial 
sample  
 
 
Positive Xpert  
N=5,592 
Xpert results 
N=10,029 
 
 
Negative Xpert 
N=4,302 
TB 
N=690 
 
No TB 
N=3,612 
 
No TB 
N=107 
 
TB 
N=5,485 
 
Indeterminate Xpert 
N=135 
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Table 3. 1: Demographic clinical and diagnostic characteristics of the study participants 
Demographic 
and clinical 
characteristics 
Belarus 
N=92 
Cambodia  
N=57 
Georgia 
N=817 
India 
 N=431 
Italy  
N=95 
Moldovia 
N=718 
Peru 
 N=4083 
South Africa  
N=1509 
Vietnam 
N=1990 
Zimbabwe 
N=102 
 
Age 41 (29-
56) 
 
39 (28-65) 39 (28-54) 31 (23-47) missing 38 (29-49) 30 (23-45) 35 (29-44) 42  (30-54) 38 (32-48) 
HIV infection 2/92 
(2.2%) 
 
0π 6/817 
(0.7%) 
2/431 α 
(0.5%) 
2/95# 
 (2.1%) 
32/718 
(4.5%) 
193/4083 
(5%) 
902/1509 
(60%) 
132/1990 
(7%) 
62/102 
(61%) 
Female sex 39/92 
(42%) 
 
33/57 
(58%) 
239/817 
(29%) 
179/431 
 (42%) 
missing 183/718 
(25.5%) 
1756/4083 
(43%) 
697/1509 
 (46%) 
550/1990 
(28%) 
51/102 
(50%) 
History of 
tuberculosis 
18/92 
(20%) 
 
0 252/817 
(31%) 
125/431 
(29%) 
1/95 
(1%) 
231/718 
(32%) 
113/4083 
(3%) 
353/1509 
(23%) 
305/1990 
(15%) 
0 
Diagnostic 
characteristics 
 
          
¥Prevalence  41/92 
(45%) 
 
36/57 
(63%) 
522/817 
(64%) 
297/431 
(69%) 
78/95 
(82%) 
650/718 
(91%) 
2378/4083 
(58%) 
694/1509 
(46%) 
1469/1990 
(74%) 
10/102 
(9.8%) 
 
S-C+ 28/41 
(68%) 
10/36 
(28%) 
229/522 
(44%) 
93/303 
(31%) 
37/78 
(47%) 
251/650 
(39%) 
347/2378 
(15%) 
293/694 
(42%) 
299/1469 
(20%) 
7/10 
(70%) 
RIF resistance 13/41 
(32%) 
1/36 
(3%) 
423/522 
(81%) 
147/297 
(49%) 
9/78 
(12%) 
519/650 
(81%) 
373/2378 
(16%) 
301/694 
(44%) 
447/1469 
(30%) 
0 
∞HIV test was not done in 98% in Brazil, α in India only 50% were tested for HIV, # in Italy 48% had unknown HIV status,π in Cambodia all tested negative 
 
Two MGIT and LJ culutres were considered. ¥ At least one positive culture 
MGIT-Mycobacterium Growith Indicator tuber for liquid culture 
LJ-Lowestein Jensen for solid culture 
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Table 3. 2:  Sensitivity of Xpert MTB/RIF by time to culture positivity  
 
Categories for analysis Pooled sensitivity of Xpert MTB/RIF using time to culture positivity as a reference standard  (95% CI) 
 
 ≤ 5 days 
(N=351) 
> 5  ≤ 10 days 
(N=2231) 
>10≤15 days 
(N=1885) 
>15≤20days 
(N=808) 
>20≤25days 
(N=296) 
>25≤30days 
(N=119) 
>30≤35days 
(N=75) 
>35≤42days 
(N=45) 
 
All culture positive 
 
99.3% 
(95.0 to 100) 
99.3% 
(98.4 to 99.7) 
96.8% 
(94.0 to 98.3) 
75.2% 
(60 to 86) 
62% 
(47.8 to 74.5) 
58.7% 
(34.5  to 79.2) 
60% 
(42.8 to 75.1) 
71.1% 
(56.3 to 82.4) 
Smear positive-culture 
positive 
 
99.6% 
(97.6 to 100) 
99.6% 
(99.3 to 99.8) 
99% 
(97 to 99.2) 
95% 
(87 to 98) 
91% 
(70 to 98) 
75% 
(48 to 90) 
87% 
(70 to 95) 
92% 
(51 to 99) 
Smear negative-culture 
positive 
 
99% 
(62 to 100) 
98% 
(80 to 100) 
92% 
(83 to 96) 
62% 
(43 to 77) 
43% 
(31 to 56) 
53% 
(20 to 83) 
50% 
(35 to 65) 
50% 
30 to 70) 
 
Sensitivity estimates and confidence interval (CI) were calculated allowing for random effect and clustering by site, only MGIT culture is considered.  
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Table 3. 3: Overall sensitivity performance of Xpert MTB/RIF test 
Groups of analysis Sensitivity  (95% CI; n/N) 
All culture positive 88.1% 
 
(81.8 to 92.5;  5485/6175) 
Smear positive-culture positive 98.6% 
 
(96.6 to 99.4; 4410/4563) 
Smear negative-culture 
positive 
64.9% (50.0  to 77.5; 1062/1592) 
HIV positive 86.7% (76.8  to 92.7;  557/686) 
HIV negative 89.7% (82.8 to 94.0 ;4307/4798) 
 
Sensitivity of Xpert MTB/RIF by time to culture positivity  
Generally, the sensitivity of Xpert decreased as time to culture positivity increased across 
categories of analysis of all culture, smear positive-culture positive and smear negative-culture 
positive Figure 3. 2. The overall median time to culture positivity was 11 days (Interquartile 
range (IQR) 8-15). Of the 5,850 participants with positive MGIT culture 76% had TTP of equal 
or less than 15 days. In all culture positive patients, the sensitivity of Xpert in categories up to 
15 days were: ≤ 5, 99.3%, (95% CI, 95-100, N=351), >5≤10, 99.3 % (95%CI, 98.4-99.7, 
N=2231)  and >10≤15, 96.8% (95%CI,94-98.3, N=1,885). In smear negative-culture positive: 
≤ 5, 99%, (95% CI, 62-100, N=37), >5≤10, 98% (95%CI, 80-100, N=237)  and >10≤15, 92% 
(95%CI,83-96 ,N=413). In HIV positive: ≤ 5, 96% , (95% CI: 63-100, N=51) , >5≤10, 98% 
(95%CI, 90-100, N=199)  and >10≤15, 94% (95%CI, 82-98 ,N=168). The sensitivity of Xpert in 
the first fifteen days was high in all three groups of analysis: all culture positive, smear positive-
culture positive and smear negative-culture negative and irrespective of HIV status. 
The sensitivity of Xpert in participants with a TTP of less than fifteen days was high in all three 
groups of analysis: all culture positive, smear positive-culture positive and smear negative- 
culture positive, Table 3. 2. This was also observed irrespective of HIV status Figure 3. 2).  
There was a substantial drop in Xpert sensitivity for smear negative-culture positive patients 
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after 15 days of TTP. For smear positive patients, there was only a small drop in sensitivity by 
TTP Table 3. 2. A similar pattern was observed for both HIV positive and negative patients 
Figure 3. 2. There was no substantial further reduction in the sensitivity of Xpert after 30 days 
to 42 days of TTP but numbers for analysis were low ,Table 3. 2. 
Figure 3. 2: Variation in Xpert sensitivity performance 
 In all culture positive    In smear negative-culture positive 
 
In all smear positive-culture positive 
 
 
Sensitivity of Xpert by different case definitions 
The overall sensitivity of Xpert was higher against a reference standard of either MGIT or LJ 
on a single sample compared to if multiple samples were used,Table 3. 4. The sensitivity of 
Xpert was highest against a single MGIT 93.4% (95% CI 87.3-96.6) in all culture positive 
patients. When only the smear negative culture positive participants when tested with a single 
MGIT were assessed, sensitivity was 78% (95% CI 58.9-89.8) .The sensitivity of Xpert was 
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91.4% (95% CI, 86.5-94.6) and 71.1% (95%CI,55.8-82.7) in all culture positive and smear 
negative -culture positive respectively against the use of multiple MGIT reference standards. 
The sensitivity of Xpert against single LJ reference standard were: 82.6% (95%CI, 64-92.7) in 
all culture positive and 68.4% (95%CI,55.1-79.3) in smear negative-culture positive. Against 
multiple LJ sensitivity of Xpert was 81.2%(95%CI,64.1-91-2) in all culture positive and 64.9% 
(95%CI,49.7-77.5) in smear negative-culture positive. Overall, the use of multiple LJ as the 
reference standard showed the lowest sensitivities. 
 
Table 3. 4:  Sensitivity performance of Xpert MTB/RIF using different tuberculosis case 
definitions 
 
Reference 
standard 
MGIT 
(N=9539) 
LJ 
(N=7260) 
All cultures 
(N=9894) 
 Single  
 
Multiple 
 
Single Multiple  
All culture 
positive 
93.4% 
(87.3 to 96.6) 
91.4% 
(86.5 to 94.6) 
82.6% 
(64.0 to 92.7) 
81.2% 
(64.1 to 91.2) 
88.2% 
(81.8 to 
92.5) 
Smear positive- 
culture positive 
98.4% 
(96.8 to 99.1) 
98.5% 
(97.1 to 99.2) 
98.7% 
(95.2 to 99.6) 
98.4% 
(94.8 to 99.5) 
98.6% 
(96.6 to 
99.4) 
Smear negative- 
culture positive 
78% 
(58.9 to 89.8) 
71.1% 
(55.8 to 82.7) 
68.4% 
(55.1 to 79.3) 
66.3% 
(54.2 to 76.6) 
64.9% 
(49.7 to 
77.5) 
 
3.1.5 Discussion  
 
We report the effect of the choice of TB definition and time to culture positivity on the 
performance of Xpert. Xpert sensitivity was consistently high in both smear positive and 
negative within 15 days of TTP, and decreased as TTP increased. Xpert sensitivity was also 
lower among smear negative-culture positive patients. We observed high sensitivity of Xpert 
when MGIT culture was used compared to LJ.  
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We observed varying performance of Xpert within different categories of TTP. It appears that 
the overall summarized sensitivity of Xpert corresponds with sensitivity of Xpert within 15 days 
of TTP and that; there is little benefit in terms of Xpert sensitivity after 20 days of TTP.  
A longer TTP corresponds to low bacterial load and smear grading and studies have shown 
low sensitivity of Xpert in low bacterial load (58, 60) consistent with our findings. Low bacterial 
load is associated with smear negative culture positive results. In this secondary data analysis, 
we did not assess bacterial load based on cycle threshold (ct) values of Xpert to accurately 
estimate bacterial load at each category due to limitation of data availability. CT values are 
inversely proportional to the number of bacterial load. However, low bacterial load at this TTP 
remains a reasonable argument. We suspect that TTP beyond 35 days could be corresponding 
to the limit of detection of Xpert. However, this remains to be demonstrated in future studies. 
Studies  have reported low sensitivity of Xpert in smear negative-culture positive compared to 
smear positive-culture positive TB (54). Among smear negative- culture positive patients, Xpert 
sensitivity substantially decreased after 15 days among HIV-negative patients. This is 
consistent with previous studies on Xpert performance among smear negative-culture positive 
patients as shown in a Cochrane review (25). Imperfect smear microscopy performance 
among patients with low bacterial load could explain the drop in Xpert sensitivity in this group. 
The confidence intervals for sensitivity of Xpert in smear negative-culture positive among HIV 
negative were so wide, not to warrant any confident conclusion.  
Xpert sensitivity dropped as TTP increased and its sensitivity beyond 20 days of TTP is 
comparable to that of smear microscopy and that at longer TTP Xpert sensitivity may be 
limited. This is relevant in sub-clinical TB. 
The use of a single culture in either MGIT or LJ showed better performance of Xpert compared 
to use of multiple cultures. Generally, we observed MGIT sensitivity outperforming LJ, 
consistent with previous finding (57, 61, 62). The downside of MGIT higher sensitivity 
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compared to LJ is the higher cost of performing MGIT. In the base-case scenario, MGIT would 
require four more USD dollars per each culture done (63).  
Our study benefits from a large dataset with patients from different epidemiological settings 
and where sample processing and testing were standards across all study sites.  A limitation 
was the lack of precise bacterial load counts in the dataset. Such an analysis would have given 
a precise explanation to the drop of sensitivity of Xpert in longer TTP in relation to the limit of 
detection of Xpert. 
We have demonstrated an effect of TTP on the accuracy of Xpert. This implies that studies 
assessing performance of diagnostic tests should also report and take into account TTP in 
order to understand differences in the performance of tests between study groups within one 
study or between different studies. In terms of clinical care, our findings underscore the need 
for clinicians to be vigilant in the diagnosis of patients with sub-clinical disease when using 
Xpert.  
Ending TB will need diagnostics with good performance in those with clinical as well as those 
with sub-clinical disease burden. As efforts to control TB increase, a change in TB 
epidemiology will demand for diagnostics with good performance, in those with sub-clinical 
disease consistent with low bacterial load. WHO has recommended the newer version of Xpert 
known as Xpert MTB/RIF ultra (Ultra) with improved sensitivity compared to Xpert particularly 
in patients with low bacterial load (24, 54). However, this will need to be weighed against the 
loss in specificity with Ultra (24, 64). 
In conclusion, Xpert sensitivity decreases with low bacterial load such as smear negative 
patients or those with longer time to culture positivity. Future evaluation studies on 
performance of diagnostic should take into account TTP and report these alongside test 
performance of diagnostics. A need to optimize existing tools such as Ultra for better accuracy 
and develop new diagnostics with better performance in those with low bacterial load remains 
relevant. Xpert sensitivity varied across different case definitions of reference standard and 
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that the use of single MGIT showed high sensitivity. More evidence is needed to establish 
whether the use of single MGIT for TB case definition is sufficient for accuracy assessment of 
diagnostics for TB. 
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To the editor 
Tuberculosis (TB) is the leading cause of mortality among infectious diseases. In 2018, 1.5 
million people died due to TB (9). Early diagnosis of TB is key in achieving WHO End TB 
targets and molecular diagnostic tests have been developed. However, molecular tests cannot 
differentiate between viable and non-viable bacteria (33, 34), leading to challenges in the 
interpretation of positive test results in patients with recent TB. 
Xpert MTB/RIF (‘Xpert’, Cepheid, Sunnyvale, USA), a widely used molecular diagnostic, 
amplifies sequences of the rpoB gene specific to Mycobacterium tuberculosis complex bacteria 
(16, 17).  Xpert has a high specificity estimated as 98% (95%CI 97 to 99) in a meta-analysis 
(25). Growing evidence from case reports or small studies and one larger study by Theron et 
al. suggests a reduced Xpert specificity among patients with TB history (33, 39, 65, 66). The 
rate of Xpert false positives are higher the more recent the history of TB (67). This poses a 
clinical dilemma: while patients with recent TB have a high risk of reinfection or relapse, they 
may also have a high risk of a false-positive result (33, 66, 67).  
To inform policy and clinical practice, we assessed  the effect of TB history on the specificity 
of Xpert by time since the previous TB episode in settings with different levels of HIV-co-
infection (68) in sixteen studies collated by FIND (Foundation of Innovative New Diagnostics, 
Geneva, Switzerland). While studies were carried out under different protocols, all used Xpert 
and a common reference standard with liquid and solid cultures that was standardized across 
studies. 
We included all presumptive patients 18 years or older with Xpert and cultures performed. 
Patients were recruited in 10 countries (Belarus, Cambodia, Georgia, India, Italy, Moldovia, 
Peru, South Africa, Vietnam and Zimbabwe) between 9 June 2011 and 6 March 2018. We 
considered Xpert results for the first sample only.  Patients with missing Xpert results were 
excluded from the analysis. 
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The reference standard was based on Lowenstein Jensen (LJ) and Mycobacterium Growth 
Indicator Tube (Bactec MGIT; BD Microbiology Systems, Cockeysville, MD, USA). Chest 
radiographs were considered compatible with TB, if the attending clinician rated the x-ray at 
least as likely for TB. We estimated the specificity of Xpert as the proportion of Xpert negative 
out of the culture negative patients. Time since previous TB treatment was calculated as the 
difference in dates between enrolment and the previous treatment completion. We estimated 
the specificity of Xpert using logistic regression with a random effect to account for clustering 
by study. All analyses were performed using Stata version 15 (stataCorp LLC, Texas, USA). 
A total of 11,583 patients had Xpert and culture results. We excluded 1,627 (1,615 missing 
Xpert results, 12 below 18 years old), leaving 10,053 patients for the analysis. Of these, 59% 
(5,900/10,053) had a positive culture and 55% were positive on Xpert. Overall 16% 
(1,630/10,053) of patients had a history of TB. The median time since previous TB treatment 
was 3 years (Interquartile range (IQR), 0.0-6). Patients with TB history tended to be older 
(median age 39 [IQR 31-48] vs 35 [IQR 26-49], HIV positive and resistant to rifampicin. 
False positive Xpert results were observed in 6.5% (95% CI 2.8 -13.7) of patients with TB 
history and 2% (95% CI 0.6-5.6) without a history of TB. In patients without previous TB, 
specificity was estimated as 98.0% (95% CI; 96.0-99.7; 3095/3164) while in those with it was 
93.5% (95% CI; 80.4-98.1; 465/501). Among the 803 participants with a TB episode within two 
years of testing, the specificity of Xpert was 92.2% (95% CI 81-97). The specificity increased 
with time since previous TB, This study represents the largest dataset to date to assess the 
effect of TB history on the specificity of Xpert for TB. The specificity of Xpert was lower in those 
with TB history compared to those without it and increased as time since previous TB 
increased. In patients with TB history within two years, specificity was reduced. False positive 
was associated with negative chest X-rays even when adjusted for TB history and HIV, 
consistent with previous findings (69). This suggests that a negative chest X-ray could aid in 
deciding whether to start a patient with a positive Xpert result and recent TB history on therapy. 
This might be a viable strategy in patients without HIV. In HIV patients, the risk of not treating 
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a patient who may truly have TB might outweigh the risk of overtreatment. These results only 
provide an association and not causation. However, the decreased specificity in patients with 
recent TB history is coupled with increased sensitivity, as shown with Xpert MTB/RIF Ultra 
(67), which supports the causal link. A causal link is further supported by an association 
between false positive results and decreasing bacterial load in those with TB history. High 
Cycle threshold values (Ct) predict false Xpert positivity however, discriminatory power of Ct 
values in predicting false positive remain minimal (39). A study showed patients with false 
positive Xpert remained healthy and asymptomatic after 17 months of follow up (69). However, 
PET-CT showed positivity consistent with active disease at the end of therapy (33, 66), 
suggesting Xpert false positivity might not stem only from non-viable bacteria alone but could 
also be related to viable bacteria still present after a patient is clinically cured. 
A limitation of our study was that Ct values for Xpert were not reported and that clinical outcome 
data were not available. Study strengths include the size of the dataset with a common 
reference standard. Data from different settings suggest likely generalizability. The overall 
specificity of Xpert in our study of 98% is identical with the pooled specificity reported in a 
recent Cochrane review including 95 studies (25).  
Our results may have implications for the design of diagnostic algorithms in patients with TB 
history, particularly if the prior episode was within two years. Consideration of other conditions 
and careful clinical decision before treatment initiation in this group is important. The impact of 
false positive results on patient outcomes remain a relevant question for future studies and 
modelling studies, such as the one by Kendall et al  for Xpert Ultra (70), should weigh the 
impact of likely overtreatment among patients with previous TB history in different 
epidemiological settings. Importantly, while our findings pertain directly to Xpert, similar results 
should be expected with other molecular TB assays. In conclusion, Xpert specificity is reduced 
among patients with previous TB history, and this reduction is greater among those with TB in 
the last two years.  
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Figure 4. 1. Between two and five years (373 participants), the specificity was 99.0% (95% CI; 
86-100) and above five years (454 participants), 98.6% (95% CI; 85.4-99.8). The rate of false 
positivity for TB detection was similar in both groups in patients with rifampicin resistance 
regardless of TB history. Of 247 patients with false positive results, 109 had chest X-ray results 
of which 75% were compatible with active TB. Patients with a non-compatible X-ray were more 
likely to have a false positive Xpert result with an odds ratio of 4.9 (95% CI; 2-11) adjusting for 
TB history, HIV, age and sex. 
This study represents the largest dataset to date to assess the effect of TB history on the 
specificity of Xpert for TB. The specificity of Xpert was lower in those with TB history compared 
to those without it and increased as time since previous TB increased. In patients with TB 
history within two years, specificity was reduced. False positive was associated with negative 
chest X-rays even when adjusted for TB history and HIV, consistent with previous findings 
(69). This suggests that a negative chest X-ray could aid in deciding whether to start a patient 
with a positive Xpert result and recent TB history on therapy. This might be a viable strategy 
in patients without HIV. In HIV patients, the risk of not treating a patient who may truly have 
TB might outweigh the risk of overtreatment. These results only provide an association and 
not causation. However, the decreased specificity in patients with recent TB history is coupled 
with increased sensitivity, as shown with Xpert MTB/RIF Ultra (67), which supports the causal 
link. A causal link is further supported by an association between false positive results and 
decreasing bacterial load in those with TB history. High Cycle threshold values (Ct) predict 
false Xpert positivity however, discriminatory power of Ct values in predicting false positive 
remain minimal (39). A study showed patients with false positive Xpert remained healthy and 
asymptomatic after 17 months of follow up (69). However, PET-CT showed positivity 
37 
 
 
consistent with active disease at the end of therapy (33, 66), suggesting Xpert false positivity 
might not stem only from non-viable bacteria alone but could also be related to viable bacteria 
still present after a patient is clinically cured. 
A limitation of our study was that Ct values for Xpert were not reported and that clinical outcome 
data were not available. Study strengths include the size of the dataset with a common 
reference standard. Data from different settings suggest likely generalizability. The overall 
specificity of Xpert in our study of 98% is identical with the pooled specificity reported in a 
recent Cochrane review including 95 studies (25).  
Our results may have implications for the design of diagnostic algorithms in patients with TB 
history, particularly if the prior episode was within two years. Consideration of other conditions 
and careful clinical decision before treatment initiation in this group is important. The impact of 
false positive results on patient outcomes remain a relevant question for future studies and 
modelling studies, such as the one by Kendall et al  for Xpert Ultra (70), should weigh the 
impact of likely overtreatment among patients with previous TB history in different 
epidemiological settings. Importantly, while our findings pertain directly to Xpert, similar results 
should be expected with other molecular TB assays. In conclusion, Xpert specificity is reduced 
among patients with previous TB history, and this reduction is greater among those with TB in 
the last two years.  
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Figure 4. 1:  Xpert MTB/RIF specificity by time since previous tuberculosis episode 
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Black circles: Specificity estimated using logistic regression with a random effect to account 
for clustering by study 
Error bars:  95% confidence intervals 
X-axis: Time period (in years)   
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Under review 
5.2 Abstract 
 
Background  
Xpert is a diagnostic test for tuberculosis (TB) with a higher sensitivity than the standard test, 
smear microscopy. Xpert has been recommended by the World Health Organization and has 
been adopted by many countries in diagnostic algorithms. However, it is not known whether a 
test with greater accuracy would translate into improved outcomes for patients.  
Objectives  
To assess the impact of Xpert on important patient outcomes for people being investigated for 
tuberculosis. Our primary outcomes were; (i) all-cause mortality during trial follow-up from time 
of first contact with health care, (ii) proportion of tuberculosis cases reported, and number of 
drug-sensitive and drug-resistant tuberculosis cases (iii) proportion of patients treated (iv) 
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proportion of treated patients who were microbiologically confirmed (v) proportion of treated 
patients who were not microbiologically confirmed.  
Search methods  
We searched for publications without language restriction in the following databases: 
Cochrane Infectious Disease Group (CIDG) Specialized Register; Cochrane Central Register 
of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE OVID; Embase 
OVID; CINAHL EBSCO; LILACS (Latin American and Caribbean Health Science Information 
database; BIREME); Science Citation Index Expanded (Web of Science), Social Sciences 
citation index (Web of Science), and Conference Proceedings Citation Index - Social Science 
& Humanities (Web of Science). We also searched the WHO International Clinical Trials 
Registry Platform, ClinicalTrials.gov, and the Pan African Clinical Trials Registry for ongoing 
trials.  
 
 
 
Selection criteria  
We included cluster-randomized trials, individually randomized controlled trials (RCTs), and 
quasi-experimental trials (pre-/post-implementation). We analyzed the randomized and non-
randomized studies separately.  
Data collection and analysis  
For each study, two review authors independently extracted data using a piloted data 
extraction tool. We assessed the quality of studies using the Cochrane risk of bias and Effective 
Practice and Organization of Care (EPOC) tools and checked for evidence of publication bias. 
We used random effect meta-analysis to allow for heterogeneity between studies in setting 
and design.  
Main results  
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We included ten studies, seven of which were randomized controlled trials and three pre-post 
intervention studies. In all domains of the Cochrane risk of bias tool, most randomized studies 
had a low risk of bias.  
There was evidence of a positive effect of Xpert on tuberculosis confirmation in treated patients 
(RR 1.29 95%CI 1.11, 1.51 in the randomized trials) and reduction in pre-treatment loss to 
follow-up (RR 0.59 95% CI 0.42-0.84). Overall there was a reduction on all-cause mortality of 
12% (RR 0.88 (95% CI 0.73, 1.05) and 24% (RR 0.76 95% CI 0.58-1.00) among HIV positive 
participants. There was evidence that Xpert lead to an increase in the overall proportion of 
patients treated for TB (RR 1.10 95%CI 0.98, 1.23), the likelihood of being cured (OR 1.09 
95% CI 1.02, 1.16), and that the proportion of those treated who were not microbiologically 
confirmed was reduced (RR 0.59 95%CI 0.41 0.85).  
Authors' conclusions  
We found that, compared with smear microscopy, our estimate suggests that Xpert reduces 
all-cause mortality by 12% although uncertainty around the effect estimate was high and the 
data is also compatible with reduction of up to 27% and an increase up to 5%. The mechanisms 
by which Xpert could affect mortality is likely at least in part related to the reduction in pre-
treatment loss to follow-up as well as increase in the proportion of patients cured. Further 
studies should assess the role of empirical treatment on the impact of Xpert on patient 
outcomes.  
5.3 Plain language summary  
 
Xpert for improving patient-important outcomes  
Xpert is a test that has been recently introduced to improve the diagnosis of tuberculosis. It is 
more accurate than the standard test, smear microscopy. However, it is not known if the 
improved accuracy translates into improvements for patients in time to diagnosis, treatment 
initiation, cure and mortality. Our aim was to assess the benefits of using Xpert focusing on 
patient outcomes. We included studies, which reported patient outcomes in those diagnosed 
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using Xpert and smear microscopy.  
What results say 
We included ten studies that were conducted in low and middle-income countries and had low 
risks of bias.  
Key findings  
Compared to smear microscopy, Xpert had an estimated 10% increase in the risk of a patient 
being initiated on treatment, (95%CI; 2% less to 23% increase), a 29% (11%, 51%) increase 
in the chance of a treated patient being microbiologically confirmed, and an estimated 
reduction in the loss of patients before treatment initiation of 41% (16% to 58% reduction). 
Xpert increased chances of being cured by 9% (2%, 16%). There was an estimated 12% 
reduction (27% reduction to 5% increase) in the risk of death for Xpert compared to smear 
microscopy. Among HIV positive, the reduction in risk of death was 24% (42% reduction to no 
reduction. We could not confidently conclude whether or not Xpert has a small beneficial effect 
on mortality.  
There is evidence that Xpert has a beneficial effect on some patient outcomes. Xpert reduces 
pre-treatment loss to follow up, increase in tuberculosis confirmation in those treated, and may 
lead to reduction in all-cause mortality. However, the range where the actual effect may be 
indicates that Xpert may make little increase in mortality.  
 
5.4 Background  
5.4.1 Description of the condition  
 
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, an obligate aerobe bacilli that 
belongs to the Mycobacteria tuberculosis complex (MTBC) (71). Transmission of tuberculosis 
most commonly occurs through the inhalation of droplets containing bacilli from a person with 
pulmonary TB who has coughed or sneezed. It is estimated that 1.7 billion people are infected 
by M. tuberculosis globally without having TB disease, and that about 5% to 15% will develop 
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TB disease (9, 72). The probability of developing TB is higher in immunocompromised 
individuals and among those infected with HIV (9). TB primarily affects the lungs (pulmonary 
tuberculosis); however, the disease can involve virtually any extra pulmonary sites in the 
human body.  
In 2018, there were 10 million new TB cases globally and people living with HIV accounted for 
8.6% of these (9). In the same year, TB was associated with 1.2 million deaths and a further 
251,000 deaths from TB disease among people living with HIV (9). The proportion of TB cases 
living with HIV was highest in the World Health Organization (WHO) African Region, 
accounting for 87% of all TB-HIV co infected cases notified (9).  
Both the emergence and under-reporting of drug resistance to antimicrobials used to treat TB 
remain major problems. In 2018, it was estimated that half a million people developed TB that 
was resistant to rifampicin (RR-TB) or multi drug resistant TB (MDR-TB), and only a third of 
these received appropriate treatment (9). MDR-TB diagnosis depends on culture 
infrastructures or line probe assays which are both expensive and not widely available at point 
of care (9, 73)  
Commonly used diagnostic techniques for TB have limitations. Culture, which is the gold 
standard for diagnosis, is normally centrally located, requires a set of bio containment 
precautions and takes up to six or eight weeks for liquid and solid culture respectively before 
results can be obtained (74). For many years, sputum smear microscopy has been the method 
used to diagnose bacteriologically confirmed tuberculosis, particularly in low- and middle-
income countries (LMICs) (74, 75), and remains the main diagnostic technique in primary 
healthcare facilities in LMICs. However, the sensitivity of smear microscopy is limited, ranging 
from 20% to 80% (75, 76), and sensitivity is further reduced in HIV-seropositive individuals 
(74). Other limitations of smear microscopy are that it is labour intensive, dependent on 
individual skills and experience, and unable to detect drug resistance (75). Consequently, there 
is a need for early, accurate and affordable diagnosis of tuberculosis, including universal drug 
susceptibility testing for all individuals being evaluated for tuberculosis (77).  
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5.4.2 Description of the intervention  
 
New molecular diagnostic tools have been developed to improve TB detection and 
decentralize drug resistance testing. The Xpert assay is an automated nucleic-acid 
amplification test. It consists of a single-use multi chambered cartridge preloaded with the liquid 
buffers and lyophilized reagent beads required for sample processing, DNA extraction, and 
hemi-nested real-time polymerase chain reaction. The assay can be used with sputum 
samples and also, with varying sensitivity, with others specimens including cerebrospinal fluid, 
lymph node tissue or aspirates, pleural fluid, ascetic fluid, urine, dialysis fluid, and pus (78, 79). 
The assay can be performed at peripheral laboratories or health facilities without biosafety 
cabinets, and minimal training for laboratory staff is required (18, 19). Xpert can detect MTBC 
and rifampicin resistance within two hours (17).  
A Cochrane Review update on the accuracy of Xpert for the detection of TB estimated the 
pooled sensitivity of the assay to be 85% and the specificity to be 98% (25). When compared 
with smear microscopy, Xpert sensitivity in smear-negative, culture-positive individuals was 
67% (25). Sensitivity was estimated to be lower in people with HIV infection (81%) than in 
those without HIV infection (88%); additionally, the Xpert assay had a pooled sensitivity of 96% 
and specificity of 98% for the detection of rifampicin resistance (25).  
In 2010, the WHO released a policy statement endorsing the Xpert assay and strongly 
recommending it as the initial diagnostic test for individuals with suspected MDR-TB and those 
with HIV. Conditional recommendations based on resource availability were made with regard 
to its use as a follow-on test for smear-negative individuals. Further recommendations for use 
in individuals with extra-pulmonary and paediatric TB were made in 2013 following new 
supporting evidence (80, 81). By the end of 2016, a total of 6,659 GeneXpert instruments and 
more than 23 million Xpert cartridges had been procured in the public sector among 130 LMICs 
under concessional pricing (52).  
There have been practical problems with the introduction of Xpert: high rates of modular failure 
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linked to an interrupted power supply were observed among early Xpert adopters in LMICs 
(82). The full impact of Xpert depends partly on a stable power supply or alternative reliable 
sources of energy such as batteries or solar energy (27). A growing number of studies have 
investigated whether the increased sensitivity of Xpert translates into an impact on patient-
important outcomes, such as time to treatment, morbidity, and mortality. These are the focus 
of this review.  
Recently, new developments aimed at improving the sensitivity of Xpert have been made by 
introducing Xpert MTB/RIF ultra (Ultra). Ultra incorporates two new multi copy amplification 
targets, known as IS6110 and IS1081, and a larger amplification chamber. In a non-inferiority 
multicenter trial, the sensitivity of Ultra was 5% higher than that of Xpert (95% confidence 
interval (CI) +2.7%, +7.8%), but the specificity was 3.2% lower (95% CI 4.7% to 2.1%) (83). 
Ultimately, a Technical Expert Consultation Group convened by the Global TB Programme of 
WHO concluded that Ultra is non-inferior to Xpert  in terms of the detection of both M. 
tuberculosis and rifampicin resistance (84). We will not focus on Ultra in this review. However, 
if we find that Xpert impacts patient-important outcomes, then it is likely that the Ultra will also 
have an impact.  
5.4.3 How the intervention might work  
 
If Xpert has a superior diagnostic accuracy compared with smear microscopy, the ability to 
detect resistance against rifampicin, near-patient utility and a fast turn-around time. It is 
expected that these features will have a positive impact on patient-important outcomes through 
beneficial diagnostic and therapeutic effects (85). The use of the assay may translate into a 
decrease in pre-diagnostic and pre-treatment loss to follow-up as well as reducing time to 
treatment. Pre-treatment loss to follow-up is associated with high mortality rates (86) and thus 
reduction in pre-treatment loss to follow-up may be expected to lead to reduction in mortality. 
Further, a larger proportion of true TB cases may receive effective therapy and fewer 
individuals may be falsely diagnosed with the disease on clinical grounds alone and incorrectly 
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treated empirically. Rapid detection of rifampicin resistance may lead to more rapid effective 
treatment initiation. These factors could improve important patient outcomes, such as 
treatment success, morbidity, mortality, and quality of life, and potentially have an impact on 
onward transmission.  
5.4.4 Why it is important to do this review  
 
Recent evidence from pragmatic trials in programmatic settings yielded largely inconclusive 
results for the impact of Xpert on different patient-important outcomes due to the limited size 
of individual studies and the large sample size required to detect (or rule out) effects of test-
treatment interventions (87, 88). Some studies suggested limited benefits of on loss to follow-
up and mortality (89, 90), whereas other studies have found that Xpert reduced time to 
treatment initiation, particularly among HIV-positive individuals (44, 91). A recent narrative 
review by (92) reported a limited impact on morbidity and mortality; however, the review 
included studies that demonstrated an impact of Xpert on increasing the diagnostic yield of 
bacteriologically confirmed TB and reducing the time to treatment initiation.  
A recent individual-patient data meta-analysis including 8,567 patients, found that Xpert 
reduced the odds of death by 12% (odds ratio 0·88, 95% CI 0·68–1·14) (48). This analysis 
summarized the results of five of the seven RCTs conducted to date (93). A very large number 
of participants are needed to conclusively demonstrate the presence or absence of an effect 
of meaningful size on mortality (87, 88, 93), and to date no single published trial has been 
sufficiently powered to obtain a conclusive result. This review will help elucidate the impact of 
this diagnostic test (and other similar tests in future), and inform the further allocation of 
resources in LMICs.  
5.5 Objectives  
 
To assess the impact of Xpert on important patient outcomes for people with TB.  
5.5.1 Types of studies  
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We include cluster- and individually- randomized controlled trials, and quasi-experimental trials 
(pre-/post implementation). We performed separate meta-analyses for randomized and non-
randomized studies.  
5.5.2 Types of participants  
 
Individuals with suspected TB presenting with one or more symptoms of the disease and able 
to provide a sputum sample.  
5.5.3 Types of interventions Intervention  
 
Diagnostic strategies that use Xpert. 
Control 
Diagnostic strategies that use smear microscopy. 
Types of outcome measures  
Primary outcomes  
 All-cause mortality during trial follow-up by time from first contact with health care 
 Proportion of TB cases reported, and number of drug-sensitive and drug-resistant 
tuberculosis cases 
 Proportion of patients treated 
 Proportion of treated patients who are microbiologically confirmed 
 Proportion of treated patients who are not microbiologically confirmed 
 Proportion cured (we defined in those cured and those completing treatment without 
evidence of failure)  
Secondary outcomes  
 Time from first contact to initiation of treatment  
 Proportion of study participants with pre-treatment loss to follow up  
 Proportion of study participants who were diagnosed with or treated for MDR/TB 
 Number of visits prior to diagnosis 
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 Patient reported satisfaction  
5.5.4 Search methods for identification of studies  
 
We identified all potential trials regardless of language or publication status (published, 
unpublished, in press, and in progress).  
Electronic searches  
We searched the following databases using the search terms detailed in page 101 Appendix 
3, from 2007 to 27 February 2018 and updated our search from 2017 to 31 July2019: Cochrane 
Infectious Disease Group (CIDG) Specialized Register; Cochrane Central Register of 
Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE OVID; Embase 
OVID; CINAHL EBSCO; LILACS (Latin American and Caribbean Health Science Information 
database; BIREME); Science Citation Index Expanded (Web of Science), Social Sciences 
citation index (Web of Science),and Conference Proceedings Citation Index - Social Science 
& Humanities (Web of Science). We also searched the WHO International Clinical Trials 
Registry Platform (www.who.int/ictrp/search/en/), ClinicalTrials.gov (clinicaltrials.gov/), and the 
Pan African Clinical Trials Registry (www.pactr.org/) to identify ongoing trials using 
(tuberculosis OR TB) AND (Xpert or GeneXpert or "sputum microbiology" or "sputum 
microscopy") as search terms.  
 
Searching other resources  
Conference proceedings  
We searched the past two years' proceedings of the International Union against Tuberculosis 
and Lung disease (UNION) conference, the Conference on Retroviruses and Opportunistic 
Infections (CROI), and the International AIDS Conference (IAS). We reviewed reference lists 
of all included studies and relevant systematic reviews. We contacted leading researchers at 
the Foundation for Innovative New Diagnostics (FIND), the WHO, Centers for Disease Control 
and Prevention (CDC), and TB-REACH to identify unpublished data as appropriate.  
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Data collection and analysis  
Selection of studies  
Two review authors (FH and MK) independently screened studies for eligibility after the 
literature search, and coded studies as either 'potentially include' or 'exclude'. Based on the 
screening results, we assessed the full-text articles of studies in the 'potentially include' 
category for eligibility using an eligibility assessment form. Differences in opinion were resolved 
through discussion. Study authors were contacted whenever clarification was needed. Multiple 
publications of the same study were included only once of the same trial: we included the 
publication including the largest sample size for the outcomes assessed and the most detailed 
information. For the additional analysis on treatment success, which was done following a 
request by the WHO guideline development group (GDG), we included another publication 
(90) of the trial in Brazil by Trajman A et al (94). All excluded studies and reasons for exclusion 
are reported in the flow diagram.  
Data extraction and management  
Two review authors (FH and MK) independently extracted data using a piloted data extraction 
tool similar to a tool previously used by our group (85). We resolved disagreements through 
discussion or by consulting a third review author (AR). We extracted the following data: study 
details (first author, year of publication), participant details, intervention, control, outcome 
measured and how it was measured, covariates, length of follow-up, and measure of effect 
with 95% confidence intervals. For binary outcomes, we extracted the relative risk or odds ratio 
if available. For time-to-event outcomes, we extracted the log hazard ratio with standard error 
or confidence interval.  
In addition, we recorded the number of participants and clusters randomized to each diagnostic 
arm, and the number of participants monitored for each outcome of interest and the number of 
events in each diagnostic arm. For cluster RCTs that were adjusted for clustering, we extracted 
the adjusted measures of effect for each outcome and method of adjustment. In studies that 
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are not adjusted for clustering, we extracted the number of clusters randomized or the mean 
cluster size and the intra class correlation coefficient (ICC), if available. We also extracted data 
relevant for the assessment of the risk of bias.  
5.5.5 Assessment of risk of bias in included studies  
 
Two review authors (FH and MK) independently assessed the risk of bias using the Cochrane 
'Risk of bias' assessment tool for assessing risk of bias in randomized studies (95), and other 
tools for assessing risk of bias in non-randomized studies (EPOC resources for reviewers 
2018: Schumacher SG 2016;). We contacted the corresponding study author for clarification 
or more information if data were missing or the procedures were unclear. We resolved all 
discrepancies through discussion or by consulting a third review author (AR). We assessed 
the risk of bias as low, high, or unclear.  
We assessed the included studies for the method of allocation sequence generation and 
allocation concealment (adequate, inadequate, not done, or unclear (as defined by Juni P et 
al (96), blinding (describing who was blinded, noting that the outcome assessors, clinicians, 
and participants cannot be blinded); completeness of information about follow-up (proportion 
of those presenting for care who were treated, who completed treatment, and who were lost 
to follow-up), outcome reporting, and selective reporting bias. For cluster-randomized trials, 
we considered additional criteria, such as baseline imbalance and incorrect analysis.  
Measures of treatment effect  
For the outcomes that assess proportions, we present the impact of Xpert using risk ratios if 
available with their 95% confidence intervals. We aimed to present the impact of Xpert on time 
to treatment using hazard ratios, if available. We used the adjusted estimates presented by 
the authors unless the covariates used would affect comparability.  
Unit of analysis issues  
We carried out the intention-to-treat (ITT) analysis based on the intervention groups. For 
clustered studies that did not consider the cluster design in the analysis, we adjust the 
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estimated variance for clustering using the ICC before including estimates in the meta-
analysis. If the ICC was not available, we aimed to use an ICC from another, similar study. If 
this was not possible, we include the study, but note that adjustment was not possible.  
Dealing with missing data  
We determined the reasons for missing data before extracting data from the studies by 
attempting to contact the respective corresponding study author.  
Assessment of heterogeneity  
We examined heterogeneity in the intervention effect between studies using a forest plot. We 
calculate the I
2 
statistic (the proportion of variance in the meta-analysis that is attributable to 
study heterogeneity).  
Assessment of reporting biases  
We assessed reporting biases using funnel plots. We checked the funnel plots for symmetry 
or asymmetry. In case of asymmetry, we used the recommended test for funnel plot asymmetry 
(97).  
Data synthesis  
We conducted analyses using Review Manager 5 (RevMan 5) (98). We used random-effects 
model as the intervention effect was expected to vary between studies due to the participant 
mix, settings, and aspects of study design and health system factors.  
Subgroup analysis and investigation of heterogeneity  
We performed subgroup analyses in the HIV-infected patients. We conducted an additional 
subgroup analysis, which was not in the protocol by analyzing mortality restricting to studies, 
which reported mortality at six months. This analysis helped to estimate the effect of Xpert at 
the completion of TB treatment. We wished to performed sub-group analysis in children, adults 
and HIV uninfected patients but sufficient data was not available. Drug sensitive and resistant 
TB could not be analyzed since data was not available in both arms of the studies.  
52 
 
 
Sensitivity analysis  
We did not perform any planned sensitivity analyses since the few unexpected circumstances 
we anticipated were not observed:  
missing data that are likely to influence the outcome; 
excluding studies with outliers that are suspected to influence the outcome; 
Excluding studies with high risk of bias that are likely to affect the outcome.  
Certainty of the evidence  
We assessed the certainty of evidence using the GRADE approach (99, 100), and GRADEpro 
GDT software (101). We rated each important outcome as described by Balshem  et al (102)  
 High: we are very confident that the true effect lies close to that of the estimate of the 
effect. 
 Moderate: we are moderately confident in the effect estimate. The true effect is likely to be 
close to the 
estimate of the effect. 
 Low: our confidence in the effect estimate is limited. The true effect may be substantially 
different from the estimate of the effect.  
 Very low: we have very little confidence in the effect estimate. The true effect is likely to be 
substantially 
different from the estimate of effect. 
RCTs start as high quality evidence but could be downgraded if there are valid reasons 
within the following five categories: risk of bias, imprecision, inconsistency, indirectness, and 
publication bias. Studies could also be upgraded if there is a large effect, and if all plausible 
residual confounding would reduce a demonstrated effect or would suggest a spurious effect 
if no effect was observed (102).  
5.6 Results  
5.6.1 Description of studies  
Results of the search  
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Our search found 1,192 records, 1,190 from the databases search after duplicates were 
removed and two from additional sources. We excluded 1,165 records after screening the 
abstracts, the remaining 27 records were fully assessed for the eligibility criteria. Out of the 27 
records, nine were studies on the accuracy of Xpert, three did not have outcome or population 
of interest, three were observational studies and two had no comparison group, with the 
remaining ten studies were eligible for inclusion, Figure 5. 1 . Lessells RJ et al (47) assessed 
the impact of Xpert on patient-important outcomes, however this study was excluded because 
the comparison arm did not use smear microscopy.  
Figure 5. 1: Flow diagram of included studies 
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5.6.1.1 Included studies  
Designs  
We included three individually randomized (44, 103, 104) and four cluster-randomized trials 
(45, 89, 91, 94), and three pre-and intervention period observational studies (49, 105, 106). 
Three cluster-randomized trials (45, 89, 91) used a parallel and one (94) a stepped-wedge 
design. The unit of the randomization for the cluster-randomized trials was primary care 
facilities served by a single laboratory (89, 94), HIV clinics (45) or calendar week in a single 
large primary care TB clinic (91). The length of follow up varied indifferent studies; two months 
(106) three months (103, 104), six months (44, 89, 91, 105) and 12 months (45).  
Settings  
Most of the studies were conducted in sub-Saharan Africa. There were four in South Africa 
(89, 91, 103, 105), one in Zimbabwe (104), one in Uganda (106), one in Malawi (45) and one 
multi-country study with sites in South Africa, Tanzania and Zimbabwe (44). The remaining 
two studies were conducted in Brazil (94) and Indonesia (49). The settings for the studies were 
the primary health facilities (44, 89, 91, 105), primary care laboratories (94), a specialized 
infectious disease hospital (104), an intensive care unit (103), a national referral hospital (106), 
public HIV clinics (45) and clinics for the management of MDR patients (49).  
Participants  
Seven studies included participants who were 18 years and above and two (49, 94) included 
all age groups. HIV co-infection was reported in all but one study (105), two studies conducted 
in an HIV clinic included only HIV-infected participants (45, 104). Patients were eligible to be 
included in the studies if they were evaluated for pulmonary tuberculosis (45, 89, 91, 94, 103, 
105, 106), were at risk of MDR-TB (49)) or were infected with HIV and on ART (104) or newly 
infected with HIV and undergoing TB screening (45).  
5.6.1.1.1 Interventions  
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All studies compared Xpert diagnostic strategies to smear microscopy strategies and 
conventional drug sensitive tests (DST), if used. Expectorate sputum samples were collected 
for Xpert and smear tests in all studies except Calligaro et al (103) where tracheal aspirate 
samples were used. All of the randomized studies collected two sputum samples for smear 
microscopy and one sputum for Xpert. In Theron et al (44) at least two expectorated sputum 
were collected, one sputum selected randomly was use for smear microscopy or Xpert and the 
other sputum underwent culture. In non- randomized trials, Yoon et al (106) collected and 
evaluated two sputum samples (early morning and spot) for smear microscopy and one extra 
spot sputum sample for Xpert, Schmidt et al (105) evaluated sputum as per National Health 
Laboratory Services (NHLS) South Africa guidelines and Van Kampen et al (49) evaluated one 
sputum sample for smear and culture pre-intervention and two samples during the intervention 
(one for Xpert, the second sample for culture and drug susceptibility testing (DST)).  
5.6.1.1.2 Outcomes  
5.6.1.1.2.1 Primary outcomes  
 
All-cause mortality was assessed at different time-points across the studies: at 6 months by 
three studies (44, 89, 91), at 3 months by two studies (103, 104), 2 months by one study (106) 
and at 12 months by one study (45). Estimates for mortality were presented as relative risks 
(RR) with the exception of odds ratios (OR) by Theron et al (44). Since odds ratios and relative 
risks are similar when the proportion is less than 10% (107), we include the odds ratio in the 
meta-analysis, Table 5. 1. 
The number of TB cases diagnosed by Xpert and smear microscopy were reported in all ten 
studies. Four studies reported the proportion of treated patients who were not microbiologically 
confirmed (45, 89, 91, 104). Treatment initiation was reported at different time points across 
the studies: within 48 hours by Calligaro et al (103) , two months by Theron et al (44), three 
months by Cox et al (91),six months by Churchyard et al (89) or within one year by Ngwira et 
al (45) of follow-up. The number of treated patients who were microbiologically confirmed was 
reported by five studies (45, 89, 91, 103, 104). Two studies (91, 94) contributed data for 
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analysis of cure outcome, Table 5. 3. Data from Durovni et al (94) was taken from another 
publication (90) of the same study. 
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Table 5. 1: Descriptive summary of studies included for all cause mortality assessment 
 
Study, year Country  Design  Settings Sample 
size 
Month 
mortality 
assessed 
No. of 
patients 
tested in 
smear group 
No. (%) 
deaths in 
smear 
group 
No. of 
patients 
tested in 
Xpert group 
No. (%) 
deaths in 
Xpert 
group 
RR P 
value 
Churchyard 
2015 
South Africa Cluster 
RCT 
Outpatient-
primary 
healthcare clinics 
4656 6 2332 116 (5) 2324 91 (3.9) 1.1 
(0.75-
1.62) 
0.61 
Cox 2014 South Africa Cluster 
RCT 
Outpatient-
primary 
healthcare clinics 
1985 6 1003 38 (3.8) 982 33 (3.4) 0.89 
(0.58-
1.75) 
0.51 
Mupfumi 
2014 
Zimbabwe RCT Outpatient-
specialized 
infectious 
disease clinic 
424 3 214 17(9.9) 210 11 (6) 0.61 
(0.29-
1.27) 
0.19 
Ngwira 2017 Malawi Cluster 
RCT 
Outpatient-HIV 
primary 
healthcare clinics 
1842 12 841 58 
(8.6 per 100 
person-
years) 
1001 55 
(6.7 per 100 
person-
years) 
0.78 
(0.58-
1.06) 
0.1 
Theron 
2014 
South Africa, 
Tanzania, 
Zambia, 
Zimbabwe 
RCT Outpatient-
primary 
healthcare clinics 
1502 6 758 63 (8) 744 58 (8) *AoR 
0.92 
(0.61-
1.39) 
0.7 
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Table 5. 2: Descriptive summary of studies included for pre-treatment loss to follow up 
 
Study, year  Country  Design  Settings Total 
number 
tested 
positive 
for TB  
Month pre-
treatment 
loss to follow 
up assessed 
Number of 
patients 
tested for 
TB in smear 
group 
Number lost to 
follow up 
before 
treatment 
initiation in 
smear group 
N (%) 
Number of 
patients 
tested for 
TB in Xpert 
group 
Number lost to 
follow up 
before 
treatment 
initiation in 
Xpert group 
N (%) 
RR P 
value 
Churchyard 
2015 
South Africa Cluster 
RCT 
Outpatient-
primary 
healthcare 
clinics 
374 1 174 26 (15) 200 34 (17) 0.96 
(0.48-
1.93) 
0.91 
Cox 2014 South Africa Cluster 
RCT 
Outpatient-
primary 
healthcare 
clinics 
424 3 167 41 (25) 257 32(13) 0.51 
(0.33-
0.77) 
0.0052 
Theron 
2014 
South Africa, 
Tanzania, 
Zambia, 
Zimbabwe 
RCT Outpatient 
primary 
healthcare 
clinics 
367 6 182 28 (15) 185 15 (8) - 0.03 
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Table 5. 3: Descriptive summary of studies included for cure 
Study, 
year 
Country  Design  Settings Total 
number 
treated for 
TB  
Number of 
patients treated 
for TB in smear 
group 
Number 
cured in 
smear group 
N (%) 
Number of 
patients treated 
for TB in Xpert 
group 
Number lost to 
follow up before 
treatment initiation 
in Xpert 
N (%) 
OR P 
value 
Cox 
2014 
South 
Africa 
Cluster 
RCT 
Outpatient-
primary 
healthcare 
clinics 
492 224 176 (78.6) 268 215 (80.2) ¶1.10 
(0.75-
1.71 
0.75 
Durovni 
2014 
Brazil Step 
wedged 
cluster RCT 
Outpatient 
primary 
healthcare 
clinics 
4088 1856 1267 (68.3) 2232 1571 (70.4) 0.92 
(0.79-
1.06) 
- 
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5.6.1.1.2.2 Secondary outcomes  
 
Time to treatment initiation was defined as the time taken from diagnosis or confirmation of TB 
to starting treatment or notification date as reported by Durovni et al (94), this was reported in 
all studies except in Calligaro et al (103). Pre-treatment loss to follow-up was reported by four 
studies (44, 89, 91, 104), Table 5. 2 
None of the studies reported either the number of visits prior to diagnosis or patient reported 
satisfaction and so these outcomes were not assessed. Drug-resistant TB diagnosis was 
reported in five studies in the Xpert arm only (44, 89, 91, 94, 103) thus, we could not compare 
the health impact of Xpert on MDR-TB. Only one study (49) reported the impact of Xpert on 
patient outcomes in MDR-TB.  
5.6.1.2 Excluded studies  
 
We excluded 17 studies, Figure 5. 1 . Nine studies assessed accuracy, three did not assess 
either the outcome of interest or the population of interest, three had no comparison group and 
two were observational studies.  
5.7 Risk of bias in included studies  
Allocation (selection bias)  
Four randomized trials (44, 45, 89, 104) had sufficient information for generation of allocation 
sequence and had a low risk of bias. One trial, Cox et al (91), had a high risk of bias since the 
randomization list was generated by the investigator and insufficient details on concealment. 
All three (49, 105, 106) non-randomized pre and post trials had a high risk of bias.  
Blinding (performance bias and detection bias)  
All seven randomized trials (41, 43-46, 91, 103) had a low risk of detection bias, while the pre 
and post trials had unclear risks. For all of the trials blinding was not feasible but knowledge of 
the diagnostic test is part of the intervention and so there was a low risk of performance bias. 
Although Theron et al (44) reported that the central laboratory personnel were blinded to 
clinical based results, the authors did not clearly indicate if clinicians who performed morbidity 
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assessment score were blinded to the allocation arm. All pre and post trials had a high risk of 
performance bias, Figure 5. 2.  
Incomplete outcome data (attrition bias)  
The five randomized trials were considered to have a low risk of attrition bias except one trial 
by Cox et al (42)  with an unclear risk. Cox et al did not clearly state what proportion of the 
unfavorable outcome was linked to loss to follow-up, since the unfavorable outcome was 
reported as a combined outcome for defaulters, death and failure. The non-randomized trials 
had a low risk of attrition bias except Yoon et al (106) which had a high risk since loss to follow-
up was significantly different between the pre- and post- intervention periods.  
Selective reporting (reporting bias)  
We did not detect any selective reporting either in the randomized or in the non-randomized 
trials. 
Other potential sources of bias  
We considered there to be an unclear risk of other biases in two randomized trials (42, 94) and 
one non-randomized trial (106) whereby the same team implemented both diagnostic 
strategies. We suspect that it is possible that healthcare workers might have introduced biases 
due to changes in behavior.  
Figure 5. 2: Summary of risk of biases for all included studies 
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5.8 Effects of interventions  
 
5.8.1 Primary outcomes 
5.8.1.1  Mortality  
 
Three randomized trials assessed the effect of Xpert on mortality at six months (42, 44, 89), at 
three months by Mupfumi et al (104) or 12 months by Ngwira et al (45). The mortality rate was 
4.7% (248/5,265) in the Xpert compared to 5.7% (292/5,144) in the smear microscopy. The 
overall risk of mortality was estimated across these time points to be RR 0.88 (0.73, 1.05) for 
Xpert compared to smear microscopy (5 RCTs, 10409 participants), Figure 5. 3. Restricting 
the analysis to the three studies which assessed mortality at six months only produced an 
estimate of RR 0.97 (95%CI: 0.77,1.23) (3 RCTs, 8143 participants), Figure 5. 5. In studies 
that had included only HIV-positive participants, mortality risk was estimated to be 0.76 
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(95%CI: 0.58, 1.00) (2 RCTs, 2239 participants), Figure 5. 4. In the non-randomized studies, 
mortality was reported in only one study (106), with a risk difference (RD) of 3% (-21%, 27%) 
between the baseline and Xpert implementation phases, favoring Xpert.  
Figure 5. 3: All cause mortality 
 
Figure 5. 4: Mortality among HIV positive population 
 
Figure 5. 5: Mortality assessed at six months 
 
 
 
 
5.8.1.2 Number of TB cases reported  
 
In six randomized trials (44, 89, 91, 94, 103, 104), the number of TB patients diagnosed was 
reported. Overall, there was a higher number of diagnosed TB patients with Xpert compared 
to smear microscopy (6,119 vs 5,750).  
5.8.1.3 Proportion of patient treated  
 
There was a tendency towards higher a proportion of patients being treated for TB in the Xpert 
compared to the smear microscopy arm, (RR 1.10 95%; 0.98, 1.23) (5RCTs, 8,793 
participants), Figure 5. 6 (42, 44, 89, 103, 104).  
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Those treated in the Xpert arm were more likely to be confirmed microbiologically than those 
treated in the smear microscopy arm were (RR 1.29 95% 1.11, 1.51) (3 RCTs, 780 
participants), Figure 5. 7 (45, 89, 91). 
A lower proportion of treated patients in the Xpert arm were confirmed compared to the smear 
microscopy arm (RR 0.59 95% 0.41, 0.85) (4 RCTs, 367 participants), Figure 5. 8 (45, 89, 91, 
104).  
Figure 5. 6:  Proportion of patients treated 
 
 
Figure 5. 7:  Proportion of treated patients, microbiologically confirmed 
 
 
Figure 5. 8: Proportion treated, who are not microbiologically confirmed 
 
 
 
5.8.1.4 Cure  
 
Xpert significantly increased the odds of being cured compared to smear microscopy (OR 1.09, 
95%CI: 1.02, 1.16) (2RCTs, 4,580 participants), Figure 5. 9 (91, 94).  
Figure 5. 9: Proportion of patients cured 
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5.8.2 Secondary outcomes  
5.8.2.1 Time to treatment initiation  
 
The hazard ratio for time to treatment initiation was reported for only one randomized study 
(91) (HR 0.76 (0.63, 0.92)) with medians of the skewed distributions for treatment initiation only 
reported in two further studies (89, 104). This outcome has been the subject of a recent 
individual patient meta-analysis by Di Tanna et al (48) which included four similar studies (44, 
89, 91, 104) with an overall estimated hazard ratio of 1.00 (0.75, 1.32) adjusting for age and 
gender. We do not replicate it here.  
5.8.2.2 Pre-treatment loss to follow-up  
 
Across three randomized trials (42, 44, 89), Xpert was found to reduce the risk of pre-treatment 
loss to follow-up with an estimated risk ratio of 0.59 (95% 0.42, 0.84) (3 RCTs, 1165 
participants), Figure 5. 10 . (44, 89, 91). 
Figure 5. 10:  Proportion of pre-treatment loss to follow up 
 
 
5.8.2.3 Drug-resistant TB  
 
A comparison between Xpert and smear strategies for outcomes specific to drug-resistant TB 
could not be made because drug-resistant TB diagnosis was reported in the Xpert arm only. 
Only one non-randomized study (49) which had assessed patient outcomes among multi-drug 
resistant TB fulfilled the inclusion criteria. Time to MDR treatment initiation was reduced by 72 
days, from median of 88 days pre-introduction to 16 days after Xpert was introduced.  
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5.8.2.4 Number of visits prior to diagnosis and patient reported satisfaction  
 
Two pre-specified secondary outcomes (number of visits prior to diagnosis, patient reported 
satisfaction) could not be analyzed due to lack of data in all of the included studies.  
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Table 5. 4: Grade table: Xpert compared to smear microscopy in adults with signs and symptoms of pulmonary tuberculosis 
Xpert compared to smear microscopy in adults with signs and symptoms of pulmonary tuberculosis 
Patient or population: adults with signs and symptoms of pulmonary tuberculosis 
Setting:  
Intervention: Xpert  
Comparison: smear microscopy 
Outcomes Anticipated absolute 
effects* (95% CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Risk with 
smear 
microscopy 
Risk with 
Xpert 
MTB/RIF 
Mortality Study population RR 0.88 
(0.73 to 
1.05) 
10409 
(5 RCTs) 
⊕⊕⊕⊝ 
MODERATE 1 
2 3 
Compared to smear microscopy Xpert showed a 
tendency towards reduction on mortality. High rates 
of empirical treatment in settings in which studies 
were conducted and insufficient sample size, 
increase in proportion of cured and reduction in pre 
treatment loss to follow up potentially explain the 
lack of statistically significant effect of Xpert on 
mortality 
57 per 1,000 50 per 
1,000 
(41 to 60) 
Cure Study population OR 1.09 
(1.02 to 
1.16) 
4580 
(2 RCTs) 
⊕⊕⊕⊕ 
HIGH 4 
Xpert increase the proportion of patients cured 
compared to smear microscopy. 694 per 1,000 712 per 
1,000 
(698 to 
724) 
Pre-treatment 
loss to follow 
up 
Study population RR 0.59 
(0.42 to 
0.84) 
1165 
(3 RCTs) 
⊕⊕⊕⊝ 
MODERATE 5 
Xpert reduces pre-treatment loss to follow up. 
182 per 1,000 107 per 
1,000 
(76 to 153) 
Study population 
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Mortality in 
HIV-positive 
participants 
71 per 1,000 54 per 
1,000 
(42 to 71) 
RR 0.76 
(0.59 to 
1.00) 
2266 
(2 RCTs) 
⊕⊕⊕⊝ 
MODERATE 6 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative 
effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of 
effect 
 
Footnotes 
1 For all randomized trials, blinding of physicians to what test was done was impossible since knowing which test was done is part of the 
intervention itself. For example, the Xpert test has higher sensitivity than smear microscopy (and also produces RIF resistance results) and 
physicians must be allowed to take this into account when deciding about patient management. While outcomes between patients may therefore 
be different due to lack of blinding this was not judged to be a source of bias but rather the mechanism through which the intervention had an 
effect. Outcome measurement could theoretically have been influenced by the lack of blinding but this was deemed unlikely to cause bias of 
important magnitude. Overall, the lack of blinding was therefore judged not to put studies at increased risk of bias.Type a message 
2 No evidence of inconsistency, four studies in the direction of showing benefit. 
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3 The 95% CI is wide likely suggesting imprecision. We caution about interpreting non-significance as no effect when the CI likely includes an 
effect that may be clinically important. We downgraded one level for Imprecision. 
4 Cure is the outcome of interest for patient important outcome. Studies have reported treatment success which includes those cured and those 
completing treatment without evidence for treatment failure . However, we did not downgrade for indirectness 
5 Variability in time for assessment of pre-treatment loss to follow up; Churchyard 2015 assessed within 28 days after enrolment, Cox 2014 
assessed by three months after enrolment and Theron 2014 assessed by the end of the study (six months) 
6 Similarly, the 95% CI is wide likely suggesting imprecision. We caution about interpreting non-significance as no effect when the CI likely includes 
an effect that may be clinically important. We downgraded one level for Imprecision 
 
 
 
 
 
 
 
 
70 
 
 
 
5.9 Discussion 
5.9.1 Summary of main results  
 
We included ten studies that assessed the effect of Xpert on health outcomes. Compared to 
diagnostic strategies using smear microscopy, the use of Xpert showed a positive effect on TB 
confirmation, reduction in treatment without confirmation, reduction in pre-treatment loss to 
follow-up, and the suggestion of a moderate reduction in all-cause mortality. Similar effects on 
all-cause mortality reduction were evident in the HIV-positive population as well as when all-
cause mortality was assessed by the end of treatment period. The use of Xpert increased the 
likelihood of cure and treatment completion in TB patients.  
5.9.2 Overall completeness and applicability of evidence  
 
This is the first Cochrane review on the impact of Xpert on patient-important outcomes. It 
includes studies carried out in low and middle income countries where 95% of cases and 98% 
of tuberculosis-related deaths occur (108). The various epidemiological settings in which the 
studies were conducted provide confidence in the generalizability of our findings in high burden 
settings. A limitation is that there have not been many studies conducted on impact of Xpert 
on patient outcomes. So far there are only seven randomized trials and none has assessed 
the impact of Xpert on patient-important outcomes in MDR-TB population (93). Another 
limitation is the variability in the duration of follow-up among studies, which may increase 
heterogeneity in the study effect estimates.  
The studies included were carried out in sub-Saharan Africa, Asia and South America, areas 
with a high burden of TB. Five studies were set in South Africa, which was one of the earliest 
countries to replace smear microscopy with Xpert, and was the leading procurer of Xpert during 
the period of this review (29).  
Our findings should be interpreted carefully in the context of healthcare systems. The quality 
of healthcare system in low and middle income countries is generally low (109). Patient-
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important outcomes such as mortality depend on improvement of surrogate endpoints before 
the impact on patient outcomes can be realized (109). Studies have shown different 
experiences in terms of gaps in healthcare cascade, for example, South Africa performed 
generally better in terms of individuals accessing TB tests, but had poor treatment outcomes 
(110). Such observations underscore the need to interpret results in context of healthcare 
system and the effect of Xpert is likely to depend on linkage between diagnosis and treatment. 
Most studies included were from countries where TB is primarily managed in the public sector. 
Health effects of Xpert may be different in countries where TB is managed in the private sector 
with poor linkage to national programmmes. Comprehensive record keeping for test results 
and patient outcomes remain relevant in demonstrating health effect of Xpert.  
We could not assess all objectives planned for this review due to limitations in data availability. 
Xpert could have an impact on outcomes such as patient satisfaction and visits to health 
facilities, which could not be assessed in this review. The outcome on cure was included 
following the request by the guideline development group for Xpert of the WHO.  
5.9.3 Quality of the evidence  
 
Overall, the quality of evidence on mortality and pre-treatment loss to follow up was judged as 
moderate whereas the quality of evidence on cure was judged as high. Mupfumi et al. did not 
specify the proportion of pre-treatment lost to follow-up but rather overall loss to follow-up at 
three months. We did not include this study in the analysis of pre-treatment loss to follow up 
nevertheless; a post hoc analysis with this study included did not change the direction of our 
findings. The lack of blinding in the pragmatic trials raises the possibility of performance and 
ascertainment biases, however included trials were pragmatically conducted hence exclude 
possibility for blinding. We judged low risk of biases in performance, ascertainment selection 
and attrition biases. An issue is the low number of trials carried out.  
In endemic settings where most of the studies included were conducted, empirical treatment 
remains relevant. Empirical treatment is done when there is no bacteriological confirmation 
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and decision to treat is based on chest X-ray and/or clinical judgement. McCarthy et al reported 
that 15% of 561 patients on TB treatment in South Africa had been initiated on treatment 
empirically (111). Empirical treatment is more common when there is a high TB and TB/HIV 
burden, a high pre-test probability for TB or when a delay in initiating treatment could result in 
severe morbidity or mortality. Empirical treatment assigns patients to treatment without 
necessarily having test results leading into non-differential misclassification, which may 
mask benefits of a test towards mortality and has been discussed in a previous review (48).  
5.9.4 Potential biases in the review process  
 
A comprehensive search was carried out as far as possible without language restriction to 
ensure all studies meeting inclusion criteria were included. Experts in the field were contacted 
to identify any additional studies. We are confident that we managed to include all relevant 
studies. The studies included are similar to a recent review (48) which has some overlap in 
outcomes. We think it unlikely that there was any selection bias or that we had missed any 
potentially eligible studies.  
5.9.5 Agreements and disagreements with other studies or reviews  
 
The estimated effect of Xpert on mortality was a 12% reduction (-27%, +5%). A similar 
conclusion was reached in a recent meta-analysis of five randomized trials using patient level 
data where an impact on mortality could neither be ruled in or out (48). In the review by (48), 
three studies (44, 89, 91) contributed data for the analysis of all-cause mortality. Our review 
included five studies, increasing the sample size, for the analysis of all-cause mortality. 
Insufficient power to detect mortality in randomized trials of diagnostic impact has been 
discussed previously (48, 93) and that even larger sample size are needed to detect impact of 
Xpert on mortality. The lack of statistical significance on impact of Xpert on mortality should be 
carefully interpreted not as the lack of public health impact of Xpert on mortality rather as 
evidence for lack of evidence on the difference (112, 113). Reduction of mortality of 12% to as 
high as 27% reduction by Xpert could result in large impact in terms of tuberculosis control 
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compared to smear microscopy. However, the evidence for existence of this difference 
remains to be demonstrated in studies with larger sample size. Mortality is an outcome that 
depends on a series of health system processes and intermediate outcomes, such as time to 
treatment initiation, before an impact of mortality can be realized. The impact of Xpert on 
mortality is likely to depend on the general improvement of healthcare systems in these 
settings (109). Among HIV-positive patient mortality, we detected a larger effect in Xpert arm 
compared to smear microscopy. A similar observation was made by Di Tanna et al (48).  
In a narrative literature review of eight trials, which assessed impact of Xpert on patient 
outcomes, none of the individual trials had reported a significant impact of Xpert on mortality 
(92). All eight studies are also included in our review. There are high rates of empirical 
treatment in settings where most trials of impact of Xpert have been carried out and this may 
influence the estimates (48). In these settings, the lack of availability or access to confirmation 
of TB particularly for smear negative patients results in the probability of disease in the patient 
lying above treatment threshold, hence empirical treatment (114). Furthermore, the standard 
of care in randomized controlled trials, such as chest X-ray availability, is generally above that 
which a TB patient would receive in programmatic settings (115). This has two possible 
implications; (i) an increase in both pre and post-test probability particularly in those previously 
treated and hence increase chances for empirical treatment (ii) artificially reduce pre-treatment 
loss to follow-up and increased chances for empirical treatment (93). It remains debatable 
whether high standards of care in randomized controlled trials introduces biases or limits 
generalizability. Arguably, high interaction between research teams and participants in terms 
study procedures and follow up in the included studies limits the intended pragmatism (115). 
Of the included studies, only Durovni et al minimally interrupted the usual standard of care. 
The use of additional resources in randomized trial above what is available in usual care and 
strengthening of routine systems reduces chances to detect effect on mortality. While high 
internal validity in randomized trials remains important for strong evidence, use of routine 
collected data would likely replicate usual care and demonstrate effect of Xpert in pragmatic 
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settings(115).  
Patients in the Xpert arms were more likely to be confirmed bacteriologically than those in the 
smear microscopy arms. Similar observation were reported in a recent meta-analysis where 
Xpert was shown to be superior for tuberculosis bacteriological confirmation (116). This finding 
is not surprising given the greater accuracy of Xpert compared to smear microscopy. In South 
Africa, the introduction of Xpert in 101 primary healthcare facilities was shown to increase the 
rate of bacteriological confirmation and reduce the rate of empirical treatment over a period of 
four years in a large population based programmatic cohort(117). Similar observations were 
made in Nepal (82). Empirical treatment has long been recommended by WHO particularly in 
resource-limited settings (118). Generally, an increase in bacteriological confirmation and 
reduction in empirical treatment has been linked to an overall reduction in tuberculosis 
notification (82, 117). It is likely that TB incidence might have decreased or that the patient had 
other disease conditions, however the impact of Xpert on TB confirmation is likely to reduce 
over diagnosis of TB.  
Xpert significantly reduced the risk of pre-treatment loss to follow-up by 41% (CI 52% to 16%) 
compared to smear microscopy and has a turnaround time for results of two hours(18) which 
enables same day results. A recent review of 23 studies from 14 countries reported 
pretreatment loss to follow-up of smear or culture positive patients ranging from 4-38% (86). 
In this review, pre-treatment loss to follow-up was commonly reported in studies from Africa 
and Asia and mortality among lost to follow up was high. In Africa where the HIV/TB co-
infection rate is high, pre-treatment loss to follow-up was associated with mortality. In Asia, 
high rates of private practice are linked to pre-treatment loss to follow-up. Long waiting times, 
repeated visits and delays in receiving results have also been associated with pre-treatment 
loss to follow-up (86).  
5.9.6 Authors' conclusions Implications for practice  
 
We found that, compared with smear microscopy, Xpert has a beneficial impact on some 
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patient outcomes supporting its use in practice. Our estimate suggests that Xpert reduces all-
cause mortality by 12% although uncertainty around the effect estimate was high and the data 
is compatible with a reduction of up to 27% and an increase of up to 5%. We found that the 
use of Xpert decreased pre-treatment loss to follow up and increased the proportion of TB 
patients cured. Xpert was shown to increase TB confirmation and reduce empirical 
treatment. The mechanism by which Xpert may affect mortality is likely at least in parts related 
to the reduction in pre-treatment loss to follow-up as well as increases in the proportion of TB 
patients cured. The impact of Xpert on pre-treatment loss to follow-up will depend on other 
health system factors such as linkage to healthcare, proper recording and how fast a patient 
is initiated on treatment following positive results.  
5.9.7 Implications for research  
 
Future studies on newly developed molecular point of care tests such as the newly GeneXpert 
Omni (Omni) platform and Xpert ultra should incorporate the assessment of patient outcomes. 
Such studies are particularly valuable when carried out in settings close to patients such as 
primary healthcare facilities. Future trials should also report the impact of Xpert on patient 
outcomes in patients with drug-resistant TB. Gaps in knowledge has been identified and the 
number of visits to health facilities and patient satisfaction could also be included in future 
studies. The effect of empirical treatment should also be investigated.  
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6 Overall discussion 
6.1 Summary of findings 
Overall, Xpert perfomance varied according to different methodogical definitions of reference 
standard in sensitivity and population of interest in specificity assessment.  
Xpert sensitivity varied within different categories of TTP. Xpert sensitivity was consistently 
high in both smear-positive culture-positive and smear-negative culture-positive within 15 days 
of TTP, and decrease as TTP increased until 30 days of TTP. A substantial drop in Xpert 
sensitivity after 30 days of TTP among smear-negative culture-positive patients was observed. 
Sensitivity reached a plateau for 30 and 42 days of TTP. In additon, Xpert sensitivity was higher 
when MGIT compared to LJ culture was used as a reference standard for case definition. The 
sensitivity of Xpert was highest in single MGIT compared to multiple cultures.  
Xpert specificity varied in patients with a history of TB. Specificity was reduced among patients 
with a history of TB. A substantial reduction in specificity was observed if the history of TB was 
within two years and   chest X-ray not compatible with TB was associated with a false-positive 
Xpert result. 
Regarding the impact of Xpert on patient relevant outcomes, we found that the use of Xpert 
showed a positive effect on TB confirmation, reduction in treatment without confirmation, 
reduction in pre-treatment loss to follow-up, and a suggestion of a moderate reduction in all-
cause mortality compared to the use of smear microscopy. Similar effects on all-cause 
mortality reduction were evident in the HIV-positive population as well as when all-cause 
mortality was assessed by the end of treatment period. The use of Xpert increased the 
likelihood of cure and treatment completion in TB patients. 
6.2 Interpretation of results  
Xpert peformance has been widely assessed against a microbiological reference standard of 
culture. Different studies have assessed Xpert perfomance against single or multiple MGIT 
and/or LJ cultures, whereby sensitivity of Xpert is assessed as the proportion of culture positive 
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that test positive by Xpert in all patients throughout the evaluation period (54). This provides 
the best average estimate of Xpert performance. However, little evidence exist on how Xpert 
perfoms, particularly how sensitivity varies as a function of   the time to culture positivity. Such 
evidence provides better understanding of Xpert sensitivity in the context of changing 
epidemiological trends as efforts for TB control are being escalated. Xpert sensitivity varies in 
different patient groups. For example, Xpert sensitivity has consistently been shown to be lower 
in smear-negative culture-positive patients compared to smear–positive culture-positive 
patients. In this thesis, similar sensitivity across the three groups of analysis within 15 days of 
TTP i.e. all culture-positive, smear-positiveculture-positive and smear-negative culture-positive 
were observed. Shorter time to positivity is generally associated with high bacterial load (58). 
It appears that at shorter TTP, the negative smear results observed in smear-negative culture-
positive could  likely be a result of imperfect smear microscopy perfomance.  
It appears also that the overall sensitivity of Xpert corresponds to the sensitivity of Xpert within 
15 days of TTP and that there is little benefit in terms of Xpert sensitivity after 20 days of TTP. 
The lower sensitivity of Xpert at longer TTP calls for better diagnostics with improved sensitivity 
such as Ultra. 
The use of MGIT  reference standard against Xpert showed better sensitivity compared to LJ, 
consistent with previous findings (57, 61, 62). Single  culture showed better sensitivity of Xpert 
compared to when using multiple cultures. The downside of MGIT higher sensitivity compared 
to LJ is the higher cost of performing MGIT and high rates of contamination from previous 
studies (61-63). Evidence from Chihota VN et al suggests that in the best-case scenario, MGIT 
would require four more USD dollars per culture compared to LJ (63). Furthermore, MGIT 
culture infrastructures are expensive to establish and maintain. In the studies analyzed in this 
thesis a low rate of contamination of less than one percent was observed, which is most likely 
explained by the use of reference laboratories and standardize protocols.  The use of MGIT 
alone for M. tuberculosis isolation has been showed to miss around six percent M. tuberculosis 
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which would grow on LJ beyond six weeks of negative MGIT (61). Overall, in settings with 
better control efforts, it is expected that patients are diagnosed earlier and TTP will be 
increased. Thus, reporting TTP is important to ensure comparability of studies to allow for 
better interpretation of results. Furthermore, the comparison against different definitions of 
culture positivity demonstrate the importance of comparability of reference standards across 
studies. 
In terms of Xpert specificity,  the observed  drop in specificity among patients with a history of 
TB was associated a negative chest X-ray result, even when adjusted for TB history and HIV. 
This suggests that a negative chest X-ray could aid in the decision-making process whether to 
start therapy in a patient with a positive Xpert result and recent TB history. This might be a 
viable strategy in patients without HIV. However, in patients with HIV, the risk of not treating 
might outweigh the risk of overtreatment. This thesis has demonstrated variability in Xpert 
performance in both sensitivity and specificity. WHO recognises the need for clinical diagnosis 
in patients in which bacteriological tests tend to have low sensitivity and in patients in which 
delaying treatment may lead to catastrophic outcomes (119). In such circumstances, WHO 
recommends the use of chest X-ray to aid rapid diagnosis even when the risk of false positive 
clinical diagnosis is high or the positive predictive value is low (119). A combination of clinical 
judgement and the use of chest X-ray will remain relevant for the diagnosis of TB at longer 
TTP and in those with a shorter history of TB. The decrease in specificity of Xpert is similar to 
the one reported for Ultra among patients with a shorter history of TB (24). Further 
investigations are needed to detemine if repeating Xpert on a second sample in this sub-
population may improve specificity as recommended for Ultra (31). 
Xpert showed an impact on some patient-important outcomes. The estimated effect of Xpert 
on mortality was a 12% reduction (-27%, +5%). In a narrative literature review of eight trials, 
which assessed impact of Xpert on patient outcomes, none of the individual trials had 
reported a significant impact of Xpert on mortality (92). All eight studies were also included in 
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the Cochrane review included in this thesis. In the review by Di Tanna et al (48), which had 
similar findings on mortality, three studies (44, 89, 91) contributed data for the analysis of all-
cause mortality. The Cochrane review in this thesis included five studies, which led to an 
increased sample size for the analysis of all-cause mortality. Yet, the statistical power 
remained overall insufficient to reliably detect effects on mortality, previously discussed for 
those randomized trials on health impact (48, 93)  
The lack of statistical significance on impact of Xpert on mortality should be interpreted 
carefully not as the lack of public health impact of Xpert on mortality, but rather as a lack of 
evidence on the difference (112, 113). The observed reduction of mortality of 12% by Xpert 
could result in a large impact in terms of TB control compared to smear microscopy. Mortality 
is an outcome that depends on a series of health system processes and intermediate 
outcomes, such as time to treatment initiation, before an impact on mortality can be realized. 
The impact of Xpert on mortality is likely to depend on the general improvement of health care 
systems in settings, in which Xpert is rolled out (109).  
High rates of empirical treatment in settings where most trials of impact of Xpert have been 
carried out may influence the estimates (48). In these settings, the lack of availability or access 
to confirmation of TB particularly for smear-negative patients results in the probability of 
disease in the patient lying above treatment threshold, hence empirical treatment (114). 
Furthermore, the standard of care in randomized controlled trials, such as chest X-ray 
availability, is generally above that which a TB patient would receive in programmatic settings 
(115), leading to (i) an increase in both pre- and post-test probability, particularly in those 
previously treated, and hence increase chances for empirical treatment, (ii) artificially reduce 
pre-treatment loss to follow-up,. It remains debatable whether high standards of care in 
randomized controlled trials introduces biases or limits generalizability.  
Arguably, high interaction between research teams and participants in terms study procedures 
and follow up in the included studies limits the intended pragmatism (115). Of the included 
studies, only Durovni et al minimally interrupted the usual standard of care through the use of 
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routine databases. The use of additional resources in randomized trial above what is available 
in usual care and strengthening of routine systems reduces chances to detect effect on 
mortality. While high internal validity in randomized trials remains important for strong 
evidence, use of routine collected data would likely replicate usual care and demonstrate effect 
of Xpert in pragmatic settings (115).  
Patients in the Xpert arms were more likely to be bacteriologically confirmed than those in the 
smear microscopy arms. Similar observation were reported in a recent meta-analysis where 
Xpert was shown to be superior for TB bacteriological confirmation (116). This finding is not 
surprising given the greater accuracy of Xpert compared to smear microscopy. Although 
empirical treatment has long been recommended by WHO, particularly in resource-limited 
settings (118), increase in TB confirmation will likely reduce empirical treatment as 
demonstrated in studies in South Africa (117) and Nepal (82). Generally, an increase in 
bacteriological confirmation and reduction in empirical treatment has been linked to an overall 
reduction in TB notification (82, 117). It is likely that TB incidence might have decreased or that 
the patient had other disease conditions, however the impact of Xpert on TB confirmation is 
likely to reduce over diagnosis of TB.  
Xpert significantly reduced the risk of pre-treatment loss to follow-up by 41% compared to 
smear microscopy and has a turn-around time for results of two hours (18) which enables same 
day results. A recent review of 23 studies from 14 countries reported pretreatment loss to 
follow-up of smear- or culture-positive patients ranging from 4-38% (86). In this review, pre-
treatment loss to follow-up was commonly reported in studies from Africa and Asia, and 
mortality among loss to follow-up was high, ranging from 0 to 82%. In Africa, where the HIV/TB 
co-infection rate is high, pre-treatment loss to follow-up was associated with mortality. In Asia, 
high rates of private practice are linked to pre-treatment loss to follow-up. Long waiting times, 
repeated visits and delays in receiving results have also been associated with pre-treatment 
loss to follow-up (86).  
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6.3 Strength and weaknesses 
This thesis has the following stengths:  the findings of variability in Xpert perfomance are 
reported from the analysis of a large dataset with patients from different epidemiological 
settings of HIV co-infection, suggesting generalizability. Furthermore, laboratory procedures 
were standardized across different protocols in all sites with a common reference standard,  
which minimizes any misclassifications. This thesis report includes the first Cochrane Review 
that provides direct evidence on the impact of Xpert on patient outcomes and informed a WHO 
guideline development group. Included studies in the review were carried out in sub-Saharan 
Africa, Asia and South America, areas with a high burden of TB, and should thus be 
generalizable in settings of intended use. 
On the other hand, few limitations were observed and can be summarized as follows; (i) 
inability to assess the corresponding bacterial load counts in different categories of TTP for 
sensitivity variability analysis because  the data on Ct values for Xpert were not reported in the 
database, hence not available. Such an analysis would have given a more precise explanation 
for the drop of sensitivity  of Xpert in longer TTP in relation to the limit of detection of Xpert as 
well as assessing the corresponding bacterial load in reduced specificity; (ii) in the Cochrane 
Review, a limitation was that there have not been many studies conducted on impact of Xpert 
on patient outcomes. So far, there are only seven randomized trials and none has assessed 
the impact of Xpert on patient relevant outcomes in MDR-TB population; iii) not all planned 
objectives for this review were assessed. This is due to limitations in data availability. Xpert 
could have an impact on outcomes such as patient satisfaction and visits to health facilities, 
which could not be assessed in the review but were initially planned. 
6.4 Implications 
Xpert is a widely used molecular diagnostic tool and is currently recommended by WHO as 
initial diagnostic tool compared to smear microscopy, should resources allow (26). This 
conditional recommendation, together with other strong recommendations for MDR-TB and 
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paeditric TB, have contributed  to Xpert being widely used in resouce limited settings, not to 
mention the concessional pricing (26, 29). To date, there are over 34 million Xpert cartridge 
that have been procured by the public sector (29). Being the most widely used molecular 
diagnostic tool, Xpert is expected to impact TB trends and to contribute to the control of TB. 
This thesis has demostrated that Xpert indeed impact patient-important outcomes and thus 
does contribute to TB control. The evidence generated from this thesis is direct. The findings 
of the Cochrane review has been presented to the WHO Guideline Development Group 
(Geneva, 3-6 December 2019) and contributed to the policy decisions for the use of Xpert. 
WHO end TB strategy aims at reducing TB incidence by 90% in 2035 (11). The reduction of 
TB incidence will indeed change the epidemiology of TB across different populations. This will 
require a better understanding of the perfomance of Xpert, particularly in sub-clinical TB. Such 
understanding will guide proper policy decisions on use of Xpert in the future. This thesis has 
shown marked reduced Xpert sensitivity at longer TTP which very likely corresponds to sub-
clinical TB. Clinical judgement and the use of chest X-ray will remain relevant in TB diagnosis, 
particularly in those with sub-clinical TB. As efforts to control TB increase, a change in TB 
epidemiology will demand for diagnostics with good performance, particulary in those cases 
with low bacterial load. WHO has recommended the newer version of Xpert known as Xpert 
MTB/RIF Ultra (Ultra) with improved sensitivity compared to Xpert, particularly in patients with 
a low bacterial load (24, 54).  However, Ultra gains in sensitivity come with the expense of a 
loss in specificity (24, 64). Furthermore, the observed reduction in specificity in patients with a 
previous history of TB, particularly in those whose history of TB is within two years, calls for 
guidance in interpreting  Xpert results in this sub- population. TB programmes will need to 
develop guidelines and algorithms on positive results in these group, and decision for 
indicaations to treat or not treat. Furthermore, consideration of other conditions and careful 
clinical decision before treatment initiation in this group of patients is warranted. Key questions 
for future research remain on  the impact of false-positive results on patient outcomes as well 
as modelling studies, such as the one by Kendall et al  for Xpert Ultra (70), and should weigh 
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the impact of likely overtreatment among patients with previous TB history in different 
epidemiological settings. 
6.5 Conclusion 
TB remains the major killer from a single infectious agent, and diagnosing  TB is still a 
challenge. The introduction of Xpert, a molecular diagnostic tool at point-of-care provides 
significant contribution to TB control and has been shown to impact patient-important 
outcomes. In order to reliaze full impact of Xpert, the strength of the health system, in which 
Xpert is rolled out, remains relevant. Methodological aspects of assesment of Xpert 
perfomance have shown variablity in Xpert sensitivity. Future studies reporting Xpert 
sensivitivity should consider reporting TTP as well to better understand performance 
characteristics. Finally, the need for algorithms guiding Xpert positive results in patient with a 
recent history of TB cannot be overemphasized. 
7 References 
 
1. Gagneux S. Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in 
Biology, Epidemiology and Control2017. 
2. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, et al. Out-of-Africa 
migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern 
humans. Nat Genet. 2013;45(10):1176-82. 
3. Cole ECC, C. E. Characterization of infectious aerosols in health care facilities: an aid 
to effective engineering controls and preventive strategies. American journal of 
infection control. 1998;26(4):453-64. 
4. Nicas MN, W. W. Hubbard, A. Toward understanding the risk of secondary airborne 
infection: emission of respirable pathogens. Journal of occupational and 
environmental hygiene. 2005;2(3):143-54. 
5. Beggs CB, Noakes CJ, Sleigh PA, Fletcher LA, Siddiqi K. The transmission of 
tuberculosis in confined spaces: an analytical review of alternative epidemiological 
models. Int J Tuberc Lung Dis. 2003;7(11):1015-26. 
6. Mathema B, Andrews JR, Cohen T, Borgdorff MW, Behr M, Glynn JR, et al. Drivers of 
Tuberculosis Transmission. J Infect Dis. 2017;216(suppl_6):S644-s53. 
7. Esmail H, Barry CE, 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent 
tuberculosis. Philosophical transactions of the Royal Society of London Series B, 
Biological sciences. 2014;369(1645):20130437. 
8. Bloom e, Barry R. . Tuberculosis: pathogenesis, protection, and control: Washington, 
DC: ASM Press; 1994. 
9. WHO. Global tuberculosis report. 2019. 
10. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The 
epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-
85 
 
 
resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet 
Respiratory Medicine. 2017;5(4):291-360. 
11. WHO. Global strategy and targets for tuberculosis prevention, care and control after 
2015. 2015. 
12. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. 
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a 
systematic review. Lancet Infect Dis. 2006;6(9):570-81. 
13. Salman H. Siddiqi SR-G. MGIT procedures manual for BACTEC™ MGIT 960™ TB 
System. FIND; 2006. 
14. Kelly W. Stinson KE, Susan Kayes, Makoto Matsumoto, Salman Siddiqi, Suguru 
Nakashima, Hiroyuki Hashizume, Juliano Timm,  Anne Morrissey,  Marra Mendoza,  
Princy Mathai. Mycobacteriology laboratory manual. 2014. 
15. UNITAID. Diagnostics Technology Landscape. 2017. 
16. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al. Evaluation of the 
analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 
2010;48(7):2495-501. 
17. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of 
Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-
patient technology. J Clin Microbiol. 2010;48(1):229-37. 
18. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid 
molecular detection of tuberculosis and rifampin resistance. The New England journal 
of medicine. 2010;363(11):1005-15. 
19. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, 
diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test 
for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation 
study. Lancet (London, England). 2011;377(9776):1495-505. 
20. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal Monte P, Pascarella M, et al. 
Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. 
Eur Respir J. 2012;40(2):442-7. 
21. MacLean E, Sulis G, Denkinger CM, Johnston JC, Pai M, Ahmad Khan F. Diagnostic 
Accuracy of Stool Xpert MTB/RIF for Detection of Pulmonary Tuberculosis in 
Children: a Systematic Review and Meta-analysis. J Clin Microbiol. 2019;57(6). 
22. Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, et al. 
Xpert((R)) MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. 
Cochrane Database Syst Rev. 2018;8:Cd012768. 
23. Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, et al. Xpert 
MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic 
review and meta-analysis. The Lancet Respiratory medicine. 2015;3(6):451-61. 
24. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert 
MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: 
a prospective multicentre diagnostic accuracy study. The Lancet Infectious Diseases. 
2018;18(1):76-84. 
25. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. Xpert 
MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin 
resistance in adults. The Cochrane database of systematic reviews. 
2019;6(6):CD009593-CD. 
26. WHO. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in 
adults and children-Policy update. 2013. 
27. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. 
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons 
have we learnt and how can we do better? Eur Respir J. 2016;48(2):516-25. 
28. Cazabon D, Suresh A, Oghor C, Qin ZZ, Kik SV, Denkinger CM, et al. Implementation 
of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress? 
Eur Respir J. 2017;50(2). 
86 
 
 
29. Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C, et al. Market 
penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis 
from 2014 - 2016. Gates Open Res. 2018;2:35. 
30. Puri L, Oghor C, Denkinger CM, Pai M. Xpert MTB/RIF for tuberculosis testing: 
access and price in highly privatised health markets. Lancet Glob Health. 
2016;4(2):e94-5. 
31. WHO. WHO Meeting Report of a Technical Expert Consultation: Non inferiority 
analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. 2017. 
32. Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, et al. Xpert 
MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in 
accuracy and clinical impact. Clin Infect Dis. 2014;58(7):970-6. 
33. Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, et al. Bacterial 
Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and 
Bacteriological Cure in Pulmonary TB. PLoS One. 2016;11(8):e0160062. 
34. Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, et al. 
Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture 
for quantification of early bactericidal activity. J Clin Microbiol. 2013;51(6):1894-8. 
35. Prakash AK, Datta B, Tripathy JP, Kumar N, Chatterjee P, Jaiswal A. The clinical 
utility of cycle of threshold value of GeneXpert MTB/RIF (CBNAAT) and its diagnostic 
accuracy in pulmonary and extra-pulmonary samples at a tertiary care center in India. 
The Indian journal of tuberculosis. 2018;65(4):296-302. 
36. Hodille E, Maisson A, Charlet L, Bauduin C, Genestet C, Fredenucci I, et al. 
Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis diagnosis 
on smear-negative respiratory samples in a French centre. Eur J Clin Microbiol Infect 
Dis. 2019;38(3):601-5. 
37. Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M. False-positive 
Xpert(R) MTB/RIF assays in previously treated patients: need for caution in 
interpreting results. Int J Tuberc Lung Dis. 2014;18(7):876-8. 
38. Hu P, Zhang H, Fleming J, Zhu G, Zhang S, Wang Y, et al. Retrospective Analysis of 
False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in 
Clinical Samples from a Referral Hospital in Hunan, China. J Clin Microbiol. 
2019;57(4). 
39. Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, et al. Xpert MTB/RIF 
Results in Patients With Previous Tuberculosis: Can We Distinguish True From False 
Positive Results? Clin Infect Dis. 2016;62(8):995-1001. 
40. Metcalfe JZ, Makumbirofa S, Makamure B, Mutetwa R, Penaloza RA, Sandy C, et al. 
Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients. Eur 
Respir J. 2015;45(5):1504-6. 
41. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, et al. 
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for 
tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert 
MTB/RIF. The Lancet Global health. 2015;3(8):e450-7. 
42. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of 
Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV 
prevalence in South Africa: a pragmatic randomised trial. PLoS medicine. 
2014;11(11):e1001760-e. 
43. Mupfumi L, Makamure B. Impact of Xpert MTB/RIF on antiretroviral therapy-
associated tuberculosis and mortality: a pragmatic randomized controlled trial. Open 
Forum Infect Dis. 2014;1(1):ofu038-ofu. 
44. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, 
accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in 
primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 
2014;383(9915):424-35. 
87 
 
 
45. Ngwira LG, Corbett EL, Khundi M, Barnes GL, Nkhoma A, Murowa M, et al. 
Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent 
Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in 
Rural Malawi: A Cluster Randomized Trial (Chepetsa). Clin Infect Dis. 
2019;68(7):1176-83. 
46. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, 
et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing 
tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS medicine. 
2014;11(12):e1001766-e. 
47. Lessells RJ, Cooke GS, McGrath N, Nicol MP, Newell ML, Godfrey-Faussett P. 
Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A 
Cluster-randomized Trial. Am J Respir Crit Care Med. 2017;196(7):901-10. 
48. Di Tanna GL, Khaki AR, Theron G, McCarthy K, Cox H, Mupfumi L, et al. Effect of 
Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data 
meta-analysis. Lancet Glob Health. 2019;7(2):e191-e9. 
49. van Kampen SC, Susanto NH, Simon S, Astiti SD, Chandra R, Burhan E, et al. 
Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant 
Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study. PLoS One. 
2015;10(6):e0123536. 
50. Mahwire TC, Zunza M, Marukutira TC, Naidoo P. Impact of Xpert MTB/RIF assay on 
multidrug-resistant tuberculosis treatment outcomes in a health district in South 
Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 
2019;109(4):259-63. 
51. WHO. Rapid Implementation of the Xpert MTB / RIF diagnostic test Technical and 
Operational ‘ How - to ’. 2011. 
52. WHO. WHO monitoring of Xpert MTB/RIF roll-out. 2016. 
53. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, 
diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test 
for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation 
study. Lancet. 2011;377(9776):1495-505. 
54. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. Xpert 
MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin 
resistance in adults. Cochrane Database of Systematic Reviews. 2019;6:CD009593-
CD. 
55. Naveen G, Peerapur BV. Comparison of the Lowenstein-Jensen Medium, the 
Middlebrook 7H10 Medium and MB/BacT for the Isolation of Mycobacterium 
Tuberculosis (MTB) from Clinical Specimens. Journal of clinical and diagnostic 
research : JCDR. 2012;6(10):1704-9. 
56. Salman HS, Sabine R-G. MGIT procedure manual for for BACTEC™ MGIT 960™ TB 
System. 2006. 
57. Hongler J, Musaazi J, Ledergerber B, Eberhard N, Sekaggya-Wiltshire C, Keller PM, 
et al. Comparison of Löwenstein-Jensen and BACTEC MGIT 960 culture for 
Mycobacterium tuberculosis in people living with HIV. HIV Medicine. 2018;19(9):654-
61. 
58. Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, et al. Xpert 
MTB/RIF Testing in a Low Tuberculosis Incidence, High-Resource Setting: Limitations 
in Accuracy and Clinical Impact. Clinical Infectious Diseases. 2014;58(7):970-6. 
59. Najjingo I, Muttamba W, Kirenga BJ, Nalunjogi J, Bakesiima R, Olweny F, et al. 
Comparison of GeneXpert cycle threshold values with smear microscopy and culture 
as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A 
cross-sectional study. PLoS One. 2019;14(5):e0216901. 
60. Bark CM, Gitta P, Ogwang S, Nsereko M, Thiel BA, Boom WH, et al. Comparison of 
time to positive and colony counting in an early bactericidal activity study of anti-
tuberculosis treatment. Int J Tuberc Lung Dis. 2013;17(11):1448-51. 
88 
 
 
61. Lu D, Heeren B, Dunne WM. Comparison of the Automated Mycobacteria Growth 
Indicator Tube System (BACTEC 960/MGIT) with Lowenstein-Jensen medium for 
recovery of mycobacteria from clinical specimens. American journal of clinical 
pathology. 2002;118(4):542-5. 
62. Muyoyeta M, Schaap JA, De Haas P, Mwanza W, Muvwimi MW, Godfrey-Faussett P, 
et al. Comparison of four culture systems for Mycobacterium tuberculosis in the 
Zambian National Reference Laboratory. Int J Tuberc Lung Dis. 2009;13(4):460-5. 
63. Chihota VN, Grant AD, Fielding K, Ndibongo B, van Zyl A, Muirhead D, et al. Liquid 
vs. solid culture for tuberculosis: performance and cost in a resource-constrained 
setting. Int J Tuberc Lung Dis. 2010;14(8):1024-31. 
64. Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, et al. False-Positive Xpert 
MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, 
and Prospective Clinical Outcomes. Journal of Clinical Microbiology. 2018;56(3). 
65. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, et al. 
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early 
sputum biomarker of response to tuberculosis treatment. The Lancet Respiratory 
medicine. 2013;1(6):462-70. 
66. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, et al. 
Persisting positron emission tomography lesion activity and Mycobacterium 
tuberculosis mRNA after tuberculosis cure. Nature medicine. 2016;22(10):1094-100. 
67. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert 
MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: 
a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76-
84. 
68. Steingart KR, Schiller I, Dendukuri N. In reply to 'False-positive Xpert(R) MTB/RIF 
assays in previously treated patients'. Int J Tuberc Lung Dis. 2015;19(3):366-7. 
69. Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, et al. False-Positive Xpert 
MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, 
and Prospective Clinical Outcomes. J Clin Microbiol. 2018;56(3). 
70. Kendall EA, Schumacher SG, Denkinger CM, Dowdy DW. Estimated clinical impact of 
the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A 
modeling study. PLoS Med. 2017;14(12):e1002472. 
71. Cook GC ZA. Manson's Tropical Diseases.: Saunders Ltd; 2008. 
72. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-
estimation Using Mathematical Modelling. PLoS Med. 2016;13(10):e1002152. 
73. WHO. The use of molecular line probe assays for the detection of resistance to 
isoniazid and rifampicin. 2016. 
74. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan 
Africa: opportunities, challenges, and change in the era of antiretroviral treatment. 
Lancet. 2006;367(9514):926-37. 
75. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. 
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and 
opportunities. Clinical microbiology reviews. 2011;24(2):314-50. 
76. Levy H, Feldman C, Sacho H, van der Meulen H, Kallenbach J, Koornhof H. A 
reevaluation of sputum microscopy and culture in the diagnosis of pulmonary 
tuberculosis. Chest. 1989;95(6):1193-7. 
77. WHO. Global strategy and targets for tuberculosis prevention, care and control after 
2015. 2014. 
78. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. 
Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic 
review and meta-analysis. Eur Respir J. 2014;44(2):435-46. 
79. Scott LE, Beylis N, Nicol M, Nkuna G, Molapo S, Berrie L, et al. Diagnostic accuracy 
of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a 
laboratory testing algorithm for South Africa. J Clin Microbiol. 2014;52(6):1818-23. 
89 
 
 
80. WHO. Automated real-time nucleic acid amplification technology for rapid and 
simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF 
assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. 
Policy update. 2013. 
81. WHO. Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’: 
practical considerations. 2014. 
82. Creswell J, Codlin AJ, Andre E, Micek MA, Bedru A, Carter EJ, et al. Results from 
early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC 
Infect Dis. 2014;14:2. 
83. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New 
Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and 
Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 
2017;8(4). 
84. WHO. WHO Meeting Report of a Technical Expert Consultation: non-inferiority 
analysis ofXpert MTB/RIF Ultra compared to Xpert MTB/RIF. 2017. 
85. Schumacher SG, Sohn H, Qin ZZ, Gore G, Davis JL, Denkinger CM, et al. Impact of 
Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic 
Review of Study Methodologies. PLoS One. 2016;11(3):e0151073. 
86. MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to 
follow-up in tuberculosis patients in low- and lower-middle-income countries and high-
burden countries: a systematic review and meta-analysis. Bull World Health Organ. 
2014;92(2):126-38. 
87. Ferrante di Ruffano L, Dinnes J, Sitch AJ, Hyde C, Deeks JJ. Test-treatment RCTs 
are susceptible to bias: a review of the methodological quality of randomized trials 
that evaluate diagnostic tests. BMC Med Res Methodol. 2017;17(1):35. 
88. Ferrante di Ruffano L, Dinnes J, Taylor-Phillips S, Davenport C, Hyde C, Deeks JJ. 
Research waste in diagnostic trials: a methods review evaluating the reporting of test-
treatment interventions. BMC Med Res Methodol. 2017;17(1):32. 
89. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, et al. 
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for 
tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert 
MTB/RIF. Lancet Glob Health. 2015;3(8):e450-e7. 
90. Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, et al. 
Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the 
Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial. 
PLoS One. 2015;10(4):e0123252. 
91. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of 
Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV 
prevalence in South Africa: a pragmatic randomised trial. PLoS Med. 
2014;11(11):e1001760. 
92. Auld AF, Fielding KL, Gupta-Wright A, Lawn SD. Xpert MTB/RIF - why the lack of 
morbidity and mortality impact in intervention trials? Trans R Soc Trop Med Hyg. 
2016;110(8):432-44. 
93. Schumacher SG, Denkinger CM. The impact of Xpert MTB/RIF-do we have a final 
answer? Lancet Glob Health. 2019;7(2):e161-e2. 
94. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, 
et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing 
tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med. 
2014;11(12):e1001766. 
95. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The 
Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. 
2011;343:d5928. 
96. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality 
of controlled clinical trials. Bmj. 2001;323(7303):42-6. 
90 
 
 
97. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-
analyses of controlled trials with binary endpoints. Statistics in medicine. 
2006;25(20):3443-57. 
98. Review Manager 5 (RevMan 5) [Computer program]. Copenhagen: Nordic Cochrane 
Centre, The Cochrane Collaboration. 2014. 
99. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE 
guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of 
clinical epidemiology. 2011;64(4):380-2. 
100. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et 
al. A GRADE Working Group approach for rating the quality of treatment effect 
estimates from network meta-analysis. Bmj. 2014;349:g5630. 
101. GRADEpro GDT [Computer program]. Version accessed 1 February 2018. Hamilton 
(ON): McMaster University(developed by Evidence Prime) 2015 [Available from: 
gradepro.org  
102. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. 
GRADE guidelines: 3. Rating the quality of evidence. Journal of clinical epidemiology. 
2011;64(4):401-6. 
103. Calligaro GL, Theron G, Khalfey H, Peter J, Meldau R, Matinyenya B, et al. Burden of 
tuberculosis in intensive care units in Cape Town, South Africa, and assessment of 
the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal 
aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of 
disease study with a nested randomised controlled trial. The Lancet Respiratory 
medicine. 2015;3(8):621-30. 
104. Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, et al. 
Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and 
Mortality: A Pragmatic Randomized Controlled Trial. Open Forum Infect Dis. 
2014;1(1):ofu038. 
105. Schmidt BM, Geldenhuys H, Tameris M, Luabeya A, Mulenga H, Bunyasi E, et al. 
Impact of Xpert MTB/RIF rollout on management of tuberculosis in a South African 
community. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 
2017;107(12):1078-81. 
106. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, et al. Impact 
of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized 
patients in Uganda. PLoS One. 2012;7(11):e48599. 
107. Sedgwick P. Relative risks versus odds ratios. BMJ. 2014;348. 
108. Desikan P. Sputum smear microscopy in tuberculosis: is it still relevant? The Indian 
journal of medical research. 2013;137(3):442-4. 
109. Pai M, Schumacher SG, Abimbola S. Surrogate endpoints in global health research: 
still searching for killer apps and silver bullets? BMJ global health. 
2018;3(2):e000755. 
110. Subbaraman R, Nathavitharana RR, Mayer KH, Satyanarayana S, Chadha VK, 
Arinaminpathy N, et al. Constructing care cascades for active tuberculosis: A strategy 
for program monitoring and identifying gaps in quality of care. PLoS Med. 
2019;16(2):e1002754. 
111. McCarthy K, Fielding K, Churchyard GJ, Grant AD. Empiric tuberculosis treatment in 
South African primary health care facilities - for whom, where, when and why: 
Implications for the development of tuberculosis diagnostic tests. PLoS One. 
2018;13(1):e0191608. 
112. Altman DG, Bland JM. Absence of evidence is not evidence of absence. Bmj. 
1995;311(7003):485. 
113. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. 
Statistical tests, P values, confidence intervals, and power: a guide to 
misinterpretations. European journal of epidemiology. 2016;31(4):337-50. 
91 
 
 
114. Boyles TH. Why do clinical trials of Xpert(R) MTB/RIF fail to show an effect on patient 
relevant outcomes? Int J Tuberc Lung Dis. 2017;21(3):249-50. 
115. Ochodo E, Kalema N, Schumacher S, Steingart K, Young T, Mallett S, et al. Variation 
in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A 
systematic review and analysis of trial design considerations [version 1; peer review: 
awaiting peer review]. 2019;4(173). 
116. Agizew T, Boyd R, Auld AF, Payton L, Pals SL, Lekone P, et al. Treatment outcomes, 
diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-
analysis. Int J Tuberc Lung Dis. 2019;23(1):82-92. 
117. Hermans S, Caldwell J, Kaplan R, Cobelens F, Wood R. The impact of the roll-out of 
rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape 
Town, South Africa. Bull World Health Organ. 2017;95(8):554-63. 
118. Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S. Meta-analysis to 
compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for 
diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis. 2013;13:507. 
119. WHO. Chest Radiography in Tuberculosis Detection: Summary of current WHO 
recommendations and guidance on programmatic approaches. 2016. 
 
92 
 
 
8 Appendix 1: 
8.1 Current diagnostics pipelines listing development phases and types of technologies reported by FIND (15) 
 
 
93 
 
 
9 Appendix 2: 
 
9.1 Characteristics of included studies in the Cochrane review 
Study ID Methods Participants Intervention Outcomes Notes 
Calligaro 
2015 
Individual randomised 
controlled trial in ICUs in four 
hospitals 
 
Participants: mechanically 
ventilated patients 
suspected for tuberculosis 
18 years old and above, 
admitted between Aug 1 
2010 and 31 July 2013. with 
no TB treatment in the 
previous 60 days 
Female: 40% in the Xpert 
arm, 41% in the smear 
microscopy arm 
HIV infection: 27% Xpert, 32 
% smear 
Settings: intensive care units 
(ICUs) in four tertiary and 
secondary hospitals in Cape 
Town 
Country: South Africa 
Sample size: 317 patients in 
total 
 
Smear and culture (control), or Xpert 
MTB/RIF and culture (intervention) of 
tracheal aspirate samples. 
 
Primary outcome:proportion of 
culture-positive patients started 
on anti-tuberculous treatment in 
each trial group 48hrs after 
enrolment 
Secondary outcomes 
 time to bacteriological 
diagnosis, 
 time to treatment 
initiation, 
the proportion of 
culture-positive 
patients started on 
antituberculous 
treatment by the end of 
the study, 
 proportion of patients 
given empirical anti-
tuberculous treatment, 
 mortality 
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Churchyard 
2015 
Two-arm, parallel, cluster-
randomised trial. A cluster 
was defined as a laboratory 
and two primary care clinics 
served by but not co-located 
with that laboratory 
 
Participants had suspected 
tuberculosis: a systematic 
sample of adults giving 
sputum for TB investigation 
18 years old and above 
Female: 62% overall 
HIV: 62% overall of whom 
33% had ever been on 
antiretroviral therapy 
Setting: primary healthcare 
clinics and laboratories in 
medium burden districts in 
four provinces 
Country: South Africa 
Sample size: 4658 patients 
in total, 10 clusters in each 
arm 
 
In the Xpert group, participants had 
one spot sputum specimen collected 
for Xpert MTB/RIF testing at the 
associated laboratory. In the 
microscopy group, participants had 
two sputum specimens collected for 
fluorescence microscopy. 
 
Primary outcome: mortality, 
measured 6 months after 
enrolment 
Secondary outcomes: 
proportion with a positive index 
test result; 
in participants with a positive 
result, initial loss to follow-up, 
defined as the proportion not 
started on tuberculosis 
treatment within 28 days of 
enrolment; 
proportion of the overall cohort 
starting tuberculosis treatment 
by 6 months from enrolment 
 
 
Cox 2014 Pragmatic prospective 
cluster randomised trial. The 
study took place in one large 
primary care facility with 
randomisation by week to the 
intervention or routine care 
Participants were 
presumptive pulmonary TB 
presenting at Ubuntu clinic in 
Khayelitisha Cape town 
18 years old and above 
Female 44.7% in the Xpert 
group and 46% in smear 
microscopy group 
Randomization was done on weekly 
basis. Each week during the study 
period was randomised to either Xpert 
MTB/RIF or smear microscopy 
Intervention: Xpert MTB/RIF 
Routine care: (smear, culture and DST 
for high risk of drug resistance) 
 
Primary outcome:proportion of 
bacteriologically confirmed TB 
cases that had not initiated 
appropriate treatment by 3 
months after enrolment 
secondary outcomes: 
 time to diagnosis, 
 time to TB treatment, 
 all-cause mortality, 
 the number of clinic 
visits prior to 
Target condition: 
Tuberculosis 
case definition: 
Bacteriological 
confirmation of TB 
(smear, Xpert or 
culture) 
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HIV infection: 59% Xpert 
group 59.7% in smear 
microscopy group 
Setting: primary healthcare 
clinic 
Country: South Africa 
Sample size:982 Xpert 
MTB/RIF arm and 1003 
smear microscopy arm 
 
appropriate TB 
treatment 
 
Durovni 
2014 
Stepped wedged cluster 
randomised trial. All 14 
laboratories started with 
smear microscopy. Two 
laboratories then switched 
overnight to the Xpert arm 
every month, so that by the 
eighth and final month of the 
trial, all clusters were in the 
Xpert arm. The unit of 
comparisons were 
laboratories and the clinics 
which use their services. 
 
Patients who had sputum 
samples sent to the study 
laboratories for the diagnosis 
of pulmonary TB between 
February and October 2012 
All age groups 
Female: 35.6% Xpert, 35.9% 
smear microscopy 
HIV infection: 7.4% Xpert, 
9.8% smear 
Settings: primary healthcare 
facilities which used the 
laboratories in the study 
Country: Brazil, the study 
was conducted in the cities 
of Manaus (three 
The diagnostic test for pulmonary TB 
was 
Intervention: Xpert 
Comparison arm: sputum smears. 
 
Primary outcome 
 notification rate of 
laboratory confirmed 
pulmonary TB by 
clinics relying on study 
laboratories’ services 
measured by the 
differences and ration 
of rates in the 
intervention versus the 
baseline period 
 time to treatment 
initiation, estimated by 
the notification date 
minus the laboratory 
result date 
Secondary outcomes 
notification rates: for 
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laboratories) and Rio de 
Janeiro (eleven laboratories) 
Sample size: 2610 Xpert, 
2050 Smear microscopy arm 
, 14 clusters 
 
 pulmonary TB despite 
a negative test result, 
 pulmonary TB without 
any laboratory result 
reported, 
 overall pulmonary TB 
irrespective of 
laboratory test result. 
 the rate of Xpert tests 
positive for rifampicin 
resistance 
 proportion of patients 
with a rifampicin-
resistant Xpert result 
confirmed by 
conventional DST 
(PPV) 
 
Mupfumi 
2014 
Single centre pragmatic 
individually randomised 
controlled trial 
 
Participants included were 
consecutive symptomatic 
and asymptomatic HIV-
infected patients initiating 
anti-retroviral . 
18 years old and above 
Female: 55% 
HIV infection 100% (HIV 
clinic) 
setting:Specialized infectious 
disease hospital 
Country: Zimbabwe 
Patients provided 2 spot sputum 
specimens at least 1 hour apart. If 
patients were unable to expectorate 
sputum, attempts were made to 
induce sputum using nebulized 6% 
hypertonic saline. Samples in the 
microscopy group had a direct smear 
performed on each sample followed 
by staining with auramine O (Leica, 
Germany). Xpert MTB/RIF assays 
were performed on direct sputum 
 
Primary outcome:proportion of 
patients who were diagnosed 
with ART-associated TB or who 
died within 3 months of 
randomisation 
 
Target condition: 
Tuberculosis 
Case definition: 
Patients with at 
least 1 positive 
Xpert or microscopy 
(for “scanty” 
samples, both 
smears needed to 
be recorded as 
“scanty”) 
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Sample size:424 
 
Ngwira LG 
2019 
Cluster randomised trial in 12 
primary healthcare centres in 
rural Thyolo district Malawi 
 
Participants included were 
newly diagnosed with HIV 
18 years old and above 
Female: 55% 
HIV infection 100% (HIV 
clinic) 
setting: primary healthcare 
facilities 
Country: Malawi 
Sample size:1842 
 
Primary healthcare clinics were 
randomised to either screen TB in 
newly HIV patients by Xpert MTB/RIF 
or light emitting diode fluorescence 
microscopy (LED FM). Symptom 
screening and sputum evaluation were 
performed on-site by trained study 
personnel, and results were provided 
to participants on the same day. 
Participants testing positive for active 
TB were referred for 
treatment.Participants with TB 
symptoms but negative Xpert or LED 
FM results were asked to return in one 
month and provided IPT at that time if 
asymptomatic.All patients with positive 
Xpert or LED FM results had sputum 
taken for confirmatory culture 
performed at a central laboratory.All 
participants were asked to return to 
study clinics for assessment every 
three months (with one extra visit 
when on IPT). 
 
Primary outcome: 
 all-cause mortality 
within 12 months 
following HIV diagnosis 
Secondary outcomes: 
 TB treatment 
outcomes, 
 TB incidence, 
 and mortality in 
subgroups of age (≤35 
versus >35 years old), 
sex, clinical stage 
(stage I/II versus III/IV), 
and ART eligibility/CD4 
count 
 
Target condition: 
Tuberculosis in 
newly diagnosed 
HIV patients 
Case definition: 
Positive Xpert 
MTB/RIF, LED FM 
or positive culture 
 
Schmidt 
2017 
Before and after evaluation 
cohort to evaluate impact of 
roll out of Xpert MTB/RIF on 
detection and treatment of 
new adults with pulmonary 
tuberculosis 
 
18 years old and above 
Adults suspected of 
pulmonary tuberculosis were 
included 
Data were collected from the 
electronic NHLS database that 
records all microbiological tests for TB 
in the region, including the type of test 
(sputum smear microscopy, Xpert 
MTB/RIF or liquid culture) and the 
result of each test. Unique individuals 
tested for pulmonary TB were 
identified by unique laboratory 
Primary outcome:Tuberculosis 
detection 
Secondary outcome: 
 Median time to 
diagnosis 
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Female:45.9% pre, 44.1% 
post 
HIV infection was not 
reported 
Setting:Primary healthcare in 
the Cape Winelands East in 
Weastern Cape. The Cape 
Winelands is a semi-rural 
area with a very high 
estimated total TB case 
notification rate of 1 400 per 
100 000 population 
Country. South Africa 
Sample size:15629 
pre/10741 post 
 
identifiers. Data from the two periods 
were compared for the proportion of 
patients investigated for TB who 
tested positive by sputum smear 
microscopy, liquid culture or Xpert 
MTB/RIF, and the proportion of 
sputum smear microscopy, liquid 
culture or Xpert MRB/RIF tests that 
were positive 
 
 Median time to 
treatment 
 
Theron 
2014 
Pragmatic randomised 
parallel group multi-centre 
trial, Eligible patients were 
randomly assigned to 
undergo either Xpert 
MTB/RIF or smear 
microscopy 
 
Eligible patients had one or 
more symptoms of TB 
according to WHO criteria, 
able to spontaneously 
expectorate two sputum 
samples, had not received 
anti-TB treatment within the 
previous 60 days, gave 
informed consent, 18 years 
old and above 
Female :43% 
HIV infection 60% 
Intervention group received Xpert 
MTB/RIFsputum testing and control 
group smear microscopy sputum 
testing 
 
Primary outcome:Tuberculosis 
related morbidity (graded using 
TB score and Karnofsky 
performance score) 
Secondary outcomes: 
Feasibility of point-of-care Xpert 
MTB/RIF testing (accuracy, 
failure rates, operator protocol 
adherence, and user 
appraisals); 
Target condition: 
Tuberculosis 
case definition: 
culture positive 
patient 
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Setting: five peri-urban 
primary healthcare 
tuberculosis clinics with 
attached or close-by 
treatment facilities and 
microscopy laboratories 
Countries: South Africa, 
Tanzania, Zambia, 
Zimbabwe 
Sample size: 758 patients 
randomised to microscopy, 
744 to Xpert 
 
Time to diagnosis (overall and 
at days 1, 2, 3, 14, 28, and 56); 
Time to anti-tuberculosis 
treatment initiation (overall and 
at days 1, 2, 3, 14, 28, and 56); 
Proportion of culture-positive 
patients not started on anti-
tuberculosis treatment (dropout) 
or lost to follow up (culture-
positive patients started on 
treatment who were not retained 
in the study 
 
Van 
Kampen 
2015 
Pre and post study 
 
Criteria: Individuals at high 
risk of MDR TB according to 
guidelines, March 2011-
March 2013 
All age-groups 
Female: pre 40%%, post 
38% 
HIV: Pre 0.8%, post 2.9% 
Setting: Three clinics 
offering programmatic 
management of drug 
resistant TB in East, Central 
and West Java in Indonesia 
Country: Indonesia 
The diagnostic approach in the pre 
period was to collect one sputum 
sample from each individual and 
conduct smear microscopy and culture 
on solid or liquid media. If the culture 
was positive for TB, an isolate was re-
cultured for first-line DST. During the 
intervention, one sputum sample was 
collected for Xpert testing and a 
second sample was used for 
diagnostic workup with culture and 
first-line DST 
 
Proportion of individuals positive 
for TB 
Second-line treatment initiation 
in rifampicin resistant TB 
patients 
Time from client registration to 
diagnosis 
Time from diagnosis to 
treatment start 
 
 
100 
 
 
Number of eligible patients: 
pre 871, post 966 
 
Yoon 2012 A Multicentre implementation 
study of Xpert MTB/RIF with 
two phases: baseline and 
implementation phase using 
a cohort of patients at 
Mulago national referral 
hospital 
 
18 years old and above 
History of cough more than 
two weeks but less than six 
months 
48% female 
HIV infection ,76% 
settings: Mulago national 
referral hospital 
Country:Uganda 
Sample size:477 
 
In the baseline phase (August 2009–
March 2010), Xpert MTB/RIF results 
were not reported to clinicians or used 
for patient management. This phase 
allowed for the collection of baseline 
data on study outcomes and was 
necessary for local validation of Xpert 
MTB/RIF performance compared with 
conventional laboratory methods. In 
the subsequent implementation phase 
(March 2010–August 2010), Xpert 
MTB/RIF results were provided to 
clinicians and were used to inform TB 
treatment decisions. Each sample 
underwent smear microscopy, Xpert 
MTB/RIF and Culture 
 
Primary outcome. Two month 
mortality 
secondary outcome: time to TB 
detection and treatment 
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10 Appendix 3: 
10.1 Search strategy 
MEDLINE OVID  
1 Xpert*.mp. 2 geneXpert*.mp. 3 Cepheid.mp. 4 near* patient.mp. 5 1 or 2 or 3 or 4  
1  (smear adj3 microscop*).mp  
2  (sputum adj3 microscopy).mp  
3  Sputum/ch, cy, mi [Chemistry, Cytology, Microbiology]  
4  6 or 7 or 8 
10 exp Tuberculosis/ 
11 tubercul*.ab. or tubercul*.ti. 
12 TB.ab. or TB.ti. 
13 Mycobacterium tuberculosis/ 
14 10 or 11 or 12 or 13 
15 5 or 9 
16 14 and 15 
17 limit 16 to yr="2007 -Current" 
This search strategy was adopted for all other electronic databases. 
 
 
11 Appendix 4 
11.1 Eligibility criteria 
Patients were eligible to be included in the analysis if they had: (i) two culture available for both first and second samples in both Mycobacterium 
Growth Indicator Tube (Bactec MGIT; BD Microbiology Systems, Cockeysville, MD, USA) and Lowenstein Jensen (LJ), (ii) had Xpert results 
available,(iii) were 18 years old and above (iv) were presumptive TB patients enrolled in studies in which clinics were linked to reference laboratories 
and (v) had a final status in the database that could be defined based on culture results and/or  clinical decision. Patients were excluded if they had 
received treatment within 60 days prior to presentation at the clinic. 
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